Yesterday's news from HQNT clearly shows the company is progressing with its come-back plans. We have very qualified people in place here who have been successful in the past with the company's medical software product line. Also, the medical manufacturing business was not sidetrack but a very good complement segment and has done well over the past year as reported in previous PR. Be sure to review them.

instaCare Corp. Elects Joel V. Brill, M.D. to Board of Directors; Noted Professor of Medicine and Chief Medical Officer of Predictive Health Brings Medical, Clinical and Business Background to instaCare

NEW YORK, Dec 15, 2005 (BUSINESS WIRE) -- instaCare Corp., ( INCA ) a leading Wi-Fi PDA technology provider to the lodging and satellite media industries, the developer of patent-pending technologies for e-health and EMR applications and the distributor of life-saving prescription drugs, today announced that Joel V. Brill, M.D. has been elected to the Company's Board of Directors.

Dr. Brill is chief medical officer of Predictive Health, LLC, which performs predictive modeling analysis of medical and pharmaceutical claims data and implements proactive care management solutions for purchasers. His areas of focus include coding and reimbursement methodologies, quality improvement, disease management and pharmaceutical analysis. He has assisted a number of employer groups and payor organizations develop and implement programs to improve patient care. He is on the Editorial Advisory Board of Managed Healthcare Executive, Gastroenterology Coding Alert, and Internal Medicine Coding Alert. Dr. Brill is also a reviewer for Formulary, and a consultant to several health care companies.

Dr. Brill has worked extensively with governmental and private payors on coverage and reimbursement issues. He is also an advisor to the American Medical Association's CPT Editorial Panel, Relative Value Update Committee, and a member of the Physician Consortium for Performance Improvement. He currently serves on the Pharmacy & Therapeutics committees for several managed care companies. He has held management positions with several managed care companies including Blue Shield of California and Prudential Health Care, and is on the Board of Directors of the American Board of Quality Assurance and Utilization Review Physicians (ABQAURP).

"Adding a recognized business leader, and a renowned clinician like Dr. Brill to our Board is a significant accomplishment for instaCare," commented Robert Cox, chairman and chief executive officer. "Dr. Brill recognizes the potential of marrying our wireless technology with a state-of-the-art drug distribution system to speed affordable drug delivery to the more than 40 million uninsured and underinsured Americans. We look forward to benefiting from his experience as we reach out to health care professionals, many of whom are Dr. Brill's business associates from his many years of experience in this industry."

Dr. Brill commented, "The availability of affordable prescription medications is perhaps the most significant issue affecting Americans today, and this is particularly key for our uninsured citizens. I believe instaCare has a unique and realistic solution to address this crisis. I am honored to be asked to join the Board of Directors, and look forward to this dynamic and exciting company to quickly grow and add to an already impressive line of businesses."

Dr. Brill is Board Certified in Internal Medicine and Gastroenterology, and has practiced for over two decades in California and Arizona. He is also an Assistant Clinical Professor of Medicine at the University of Arizona School of Medicine, an Adjunct Assistant Professor of Medicine at the Arizona College of Osteopathic Medicine, and a lecturer at the School of Health Management & Policy at the WP Carey School of Business at Arizona State University. Working with the Rural Health Office at the University of Arizona, he played a role in developing a model enabling American Indian tribes to privatize their health care system from the Indian Health Service. Dr. Brill was appointed by the Arizona Board of Regents to the Arizona Area Health Education Centers Commission, and is a member of the Arizona Health Care Cost Containment System (AHCCCS) task force on Health Care Coverage in Arizona.

About instaCare Corp.

instaCare Corp. is an emerging fulfillment provider of prescription drugs through several profitable and opportunity laden medical distribution channels. The company is also a leading provider of Internet-enhanced PDA devices applicable to healthcare, lodging, and satellite rebroadcast industries. Its proprietary enterprise products ResidenceWare, MD@Hand and Satelink manage critical data, enhance productivity and e-commerce, and facilitate communication. For further information, please visit www.instacare.net or www.caredecision.net.

Forward Looking Statements:

This release contains forward-looking statements about our business or financial condition that reflect our assumptions and beliefs based on information currently available. We can give no assurance that the expectations indicated by such forward-looking statements will be realized. There may be other risks and circumstances that we are unable to predict. When used in this release, words such as "believes," "expects," "forecasts," "intends," "projects," "plans," "anticipates," "estimates" and similar expressions are intended to identify forward-looking statements, although there may be certain statements not accompanied by such expressions.

SOURCE: instaCare Corp.

instaCare Corp.
Keith Berman, 805-446-1973
kmb@instacare.net
or
Investor Relations Contacts:
Lippert/Heilshorn & Associates, Inc.
212-838-3777
Kim Sutton Golodetz, kgolodetz@lhai.com
or
Lisa Lindberg, llindberg@lhai.com


Copyright Business Wire 2005

Paulson Investment Company Makes Equity Investment in Universal Guardian to Fuel 2006 Growth

NEWPORT BEACH, Calif., Dec 14, 2005 /PRNewswire-FirstCall via COMTEX/ -- Universal Guardian Holdings, Inc. ( UGHO ), an emerging global leader in non-lethal protection products, integrated transportation security and inventory tracking systems and strategic security services to protect against terrorist, criminal and security threats to governments and businesses worldwide, today announced the closing of a $710,000 direct investment of its common stock and warrants. Under the terms of the transaction, Universal Guardian agreed to sell 1,420,000 shares to Paulson Investment Company at a price of $0.50 per share and warrants that will raise an additional $710,000 if exercised during a period up to two years.

"The investment by Paulson Investment Company represents a striking commitment to facilitate the execution of Universal Guardian's growth strategy, by providing our company with the resources necessary to ramp manufacturing production to meet current and growing demand for our Cobra StunLight(TM) product from law enforcement agencies in the United States as well as our international distributors. Paulson Investment Company has a successful and well established reputation in the law enforcement sector for new issues, including initial investments in Taser International (TASR) and Icop Digital (ICOP)," stated Michael Skellern, President and CEO of Universal Guardian. "We look forward to working with Paulson Investment Company as our investment bankers to meet the needs of our rapidly growing company. We also expect that this financing will meet all our near-term capital requirements as we project substantial revenue increases and profitability for 2006," continued Mr. Skellern.

Paulson Investment Company has a 35 year history as a leading national investment company and is the Northwest's largest independent brokerage firm and a leading Investment Banker for emerging companies nationwide.

About Universal Guardian Holdings, Inc.

Universal Guardian Holdings, Inc. (UGHO) and its subsidiaries provide a comprehensive range of security products, systems, and services designed to mitigate terrorist and security threats worldwide. Universal Guardian Global Security Group comprises everything from strategic and tactical security services, business risk solutions, integrated and interoperable security systems, to non-lethal defense products. Universal Guardian companies features a wide variety of security applications for transportation and global supply chain security, maritime security and critical infrastructure protection for government and multi-national businesses on every continent. www.UniversalGuardian.com

About ISR Systems Corporation

ISR Systems Corporation a wholly owned subsidiary of Universal Guardian Holdings, Inc., provides multi-level secure, security systems that facilitate surveillance, threat detection and tracking to protect inter-modal transportation, seaport and airport facilities, and critical infrastructure from asymmetrical terrorist and security threats. ISR's Trusted Shipper(TM) program incorporates government security mandates with modular, turn key source-based RFID systems and other high technology based tracking systems to provide end-to-end supply chain efficiencies, visibility and security with automated monitoring and decision support from command and control centers in North America, Europe and Asia to coordinate notification to shippers, customers and tactical responses among multiple agencies to interdict or respond to potential security threats. www.ISRsystems.com

About Shield Defense International

Shield Defense International (SDI), a wholly-owned subsidiary of Universal Guardian Holdings, Inc., designs and produces non-lethal weapons and systems that provide law enforcement, military, professional security and consumers with multiple use-of-force options to address appropriate threat conditions in today's growing global security and terrorist environments. www.ShieldDefense.com

About Secure Risks Limited

SecureRisks, a wholly owned subsidiary of Universal Guardian Holdings, Inc, is a London-based global security group providing practical risk solutions, tactical security products and services, and critical infrastructure protection in today's most challenging environments from regional hubs located in the United States, United Kingdom, Europe, South America, Middle East, Africa, Central Asia and Asia Pacific. www.SecureRisks.com

Safe Harbor Statement:

In this news release we make a number of statements, referred to as "forward-looking statements", which are intended to convey our expectations or predictions regarding the occurrence of possible future events or the existence of trends and factors that may impact our future plans and operating results, including statements relating to projected demand for our Cobra StunLight(TM) and other products and services, increases in sales revenues, and satisfaction of our capital requirements. Any statements in this news release that are not statements of historical fact maybe considered to be forward-looking statements. These forward-looking statements are derived, in part, from various assumptions and analyses we have made in the context of our current business plan and information currently available to us and in light of our experience and perceptions of historical trends, current conditions and expected future developments and other factors we believe to be appropriate in the circumstances. You can generally identify forward-looking statements through words and phrases such as "seek", "anticipate", "believe", "estimate", "expect", "intend", "plan", "budget", "project", "may be", "may continue", "may likely result", and similar expressions. When reading any forward-looking statement you should remain mindful that actual results or developments may vary substantially from those expected as expressed in or implied by that statement for a number of reasons or factors, such as those relating to: (1) whether or not markets for our products and services develop and, if they do develop, the pace at which they develop; (2) our ability to attract the qualified personnel to implement our growth strategies, (3) our ability to develop sales, marketing and distribution capabilities; (4) the accuracy of our estimates and projections; (5) our ability to fund our short-term and long-term financing needs; and (6) changes in our business plan and corporate strategies. Each forward-looking statement should be read in context with, and with an understanding of, the various other disclosures concerning our company and our business made in this news release as well as other public reports we file with the SEC, as they may be amended. You should not place undue reliance on any forward-looking statement as a prediction of actual results or developments. We are not obligated to update or revise any forward-looking statement contained in this news release to reflect new events or circumstances unless and to the extent required by applicable law.

Further information is available on the Company's website: www.UniversalGuardian.com

Investor Relations Contact:

Investor Relations
Universal Guardian Holdings, Inc.
4695 MacArthur Court., Suite 300
Newport Beach, CA USA 92626
+ 1 949. 861.8295 ext. 211

Company Contact:

Michael J. Skellern, Chief Executive Officer
Universal Guardian Holdings, Inc.
4695 MacArthur Court, Suite 300
Newport Beach, CA USA 92626
+ 1 949. 861.8295


SOURCE Universal Guardian Holdings, Inc.

Investor Relations, ext. 211, or Michael J. Skellern, Chief Executive Officer, both
of Universal Guardian Holdings, Inc., +1-949-861-8295

http://www.prnewswire.com


Copyright (C) 2005 PR Newswire. All rights reserved.

H-Quotient Announces Management Team
12/14/2005 12:38:23 PM

VIENNA, VA, Dec 14, 2005 (MARKET WIRE via COMTEX) -- H-Quotient, Inc., ( HQNT ) announced the appointment of Dr. Spurgeon Webber to the Board of Directors. He will be replacing Marc Nathan and Dr. J. Brian Copley. Dr. Thomas Laipply will serve as the Chief Scientific Advisor. Tom Hewitt will continue as the Chief of Technology.

Dr. Webber and Dr. Laipply have extensive backgrounds on the medical input side of medical software development. Dr. Webber was a Board member of IntelliServices, Inc., and he is thoroughly familiar with PhysicianQuotient. Dr. Laipply developed the Company's LabQuotient software. Mr. Hewitt is the primary technical force behind the Company's PhysicianQuotient and LabQuotient software.

Dr. Webber is a graduate of Duke University, a member of the Carolinas Medical Center teaching staff, and the head of a multiple-office dental practice. He was involved in the development of IntelliServices' medical software.

Dr. Laipply, a senior hematopathologist, is a graduate of Northwestern University Medical School, the author of numerous publications, and the holder of several patents.

Mr. Hewitt has a degree in computer science and 22 years experience in technology systems that include the development of advanced medical software systems, an automated securities system, and a fixed income securities trading system. He also serves as a vice president and the derivative trading system architect at a major bank.

This announcement may contain, in addition to historical information, certain forward-looking statements that involve risks and uncertainties. There is no assurance that this transaction will be completed. Such statements reflect management's current views and are based on certain assumptions. Actual results could differ materially from the assumptions currently anticipated.

For more information visit the H-Quotient web site at http://www.hquotient.com.

Contact:
H-Quotient, Inc.
(703) 821-3434


SOURCE: H-Quotient, Inc.

Copyright 2005 Market Wire, All rights reserved.

European Cancer Center Unveils CT Laser Mammography Technology

FORT LAUDERDALE, Fla., Dec 14, 2005 /PRNewswire-FirstCall via COMTEX/ -- Imaging Diagnostic Systems, Inc. ( IMDS ) reported that that the CT Laser Mammography (CTLM(R)) system was officially introduced to the Polish medical community and public at the opening ceremonies of the Center of Prophylactic and Early Cancer Diagnosis at the Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology on November 16th, 2005, in Gliwice, Poland.

Professor Boguslaw Maciejewski, MD, PhD, FACR, Director of the Institute of Oncology, began the day-long program with a press conference featuring a panel of oncology physicians and industry leaders. The panel stressed the capabilities of the Polish Institute of Oncology, especially the Gliwice Branch, which was recently updated with the latest innovations. Panel member Tim Hansen, IDSI Chief Executive Officer, spoke about the CTLM system's advanced technologies. The interview was followed by a public grand opening conference and ceremony featuring the panel members.

Hosted tours of the Center highlighted many cutting-edge modalities. Several ribbon-cutting ceremonies unveiled advances in MRI imaging, radiation treatment planning, ultrasound, and CT Laser Mammography, among others.

"The Institute of Oncology is our premiere reference site in Europe, featuring two CTLM systems and a significant patient caseload," commented Hansen. "They have completed over 1,500 laser mammography patient studies and serve over 7 million people in their region. Our partnership with the Institute enables us to explore routine diagnostic CTLM imaging as well as applications in oncology. Our research areas involve innovative studies, such as CTLM applicability to estimation of tumor regression rates and local tumor clearance, as well as correlations between CTLM and mammography images with molecular biomarkers. Through our collaboration, we are gaining valuable insights; we look forward to seeing the Center publish their findings."

The ceremony and CTLM debut was broadcast on television and radio stations throughout Poland, along with interviews with Professor Maciejewski that discussed breast studies and new diagnostic and screening capabilities in the Gliwice region. An educational program on new techniques in breast imaging, highlighting the CTLM system, is also being developed, with the help of EDOMED, IDSI's exclusive distributor in Poland. The 30-minute program is scheduled to air on December 22nd on Poland's national television station, TVP1.

The Institute of Oncology, a Comprehensive Cancer Center, has been registered by the Organization of European Cancer Institutes (O.E.C.I.) as a European Comprehensive Cancer Centre of Excellence since 2002.

The CTLM(R) system is the first patented breast imaging system that utilizes state-of-the-art laser technology and patented algorithms to create 3-D cross-sectional images of the breast. It is a non-invasive, painless examination that does not expose the patient to radiation or require breast compression. Imaging Diagnostic Systems has received CE Marking, CMDCAS (Canada), Canadian License, China SFDA approval, UL listing, ISO 9001:2000-13488 certification and FDA export certification for its CT Laser Breast Imaging system. The Company is seeking PreMarket Approval (PMA) from the Food and Drug Administration (FDA) for its CTLM(R) system to be used as an adjunct to mammography.

Please visit Imaging Diagnostic Systems' website at: http://www.imds.com for additional information.

In conjunction with the provisions of the Safe Harbor section of the Private Securities Litigation Reform Act of 1995, this news release may contain forward-looking statements pertaining to future anticipated projected plans, performances and developments, as well as other statements relating to future operations. All such forward-looking statements are necessarily only estimates of future results and there can be no assurance that actual results will not materially differ from expectation. Further information on potential factors that could affect Imaging Diagnostic Systems, Inc., is included in the Company's filing with the Securities Exchange Commission.

Investor Relations:
Rick Lutz
404-261-1196
lcgroup@mindspring.com


SOURCE Imaging Diagnostic Systems, Inc.

Rick Lutz, +1-404-261-1196, or lcgroup@mindspring.com, for IMDS

http://www.prnewswire.com


Copyright (C) 2005 PR Newswire. All rights reserved.

grandpappy, Nice to see someone posting logic and facts here for a change. Good job. INCA should do well in 2006 and those investors who accumulate large positions at these very cheap prices have the potential to be greatly rewarded when the real climb begins.

Universal Guardian Launches Global Command and Control Center Operating Platform to Support RFID Network and Global Security Monitoring

NEWPORT BEACH, Calif., Dec 13, 2005 /PRNewswire-FirstCall via COMTEX/ -- Universal Guardian Holdings, Inc. ( UGHO ), an emerging global leader in non-lethal protection products, integrated transportation security systems and strategic security services to protect against terrorist, criminal and security threats to governments and businesses worldwide, today announced that its ISR Systems subsidiary has deployed its "GC3" Global Command and Control Center network to support its security monitoring operations worldwide... 24 hours a day, 365 days a year.

"Our GC3 Global Command & Control Centers will facilitate worldwide data consolidation of our sourced-based RFID systems and enable real-time intermodal container tracking capabilities to deliver end-to-end supply chain security and visibility that enhances just in time inventory management efficiencies to wide spectrum of commercial and government clients," stated Michael Skellern, Universal's CEO.

"Our GC3 Command and Control Centers will provide our Secure Risks' global operations with round-the-clock security and network monitoring in addition to help desk accessibility from a secure, 'locked down' data center," stated Christopher J. Terry, ISR Systems Vice President of Network Operations. "Our proprietary system design allows for seamless integration of new customers, utilizing the latest extreme servers from Sun Microsystems. Our technology and systems can activate and implement complete production systems in a matter of a few days rather than several weeks. Combined with state of the art network security tools and a 24 x 365 availability, ISR Systems can offer the highest possible service levels in the field," continued Mr. Terry.

"ISR Systems has developed a sophisticated RFID and GPS based intermodal transportation tracking technology that utilizes EPC based asset tracking solutions. Our ground-breaking Container Guardian(TM) system is compliant with C-TPAT and CSI guidelines. Data generated from multiple sources throughout the tracking system can be consolidated in our GC3 Centers which can be manned by our staff at each of our global offices which monitor incoming alerts and initiate coordinated responses to security threats worldwide," stated Herbert P. Goertz, ISR Systems President.

About Universal Guardian Holdings, Inc.

Universal Guardian Holdings, Inc. (UGHO) and its subsidiaries provide a comprehensive range of security products, systems, and services designed to mitigate terrorist and security threats worldwide. Universal Guardian Global Security Group comprises everything from strategic and tactical security services, business risk solutions, integrated and interoperable security systems, to non-lethal defense products. Universal Guardian companies features a wide variety of security applications for transportation and global supply chain security, maritime security and critical infrastructure protection for government and multi-national businesses on every continent. www.UniversalGuardian.com

About ISR Systems Corporation

ISR Systems Corporation a wholly owned subsidiary of Universal Guardian Holdings, Inc., provides multi-level secure, security systems that facilitate surveillance, threat detection and tracking to protect inter-modal transportation, seaport and airport facilities, and critical infrastructure from asymmetrical terrorist and security threats. ISR's Trusted Shipper(TM) program incorporates government security mandates with modular, turn key source-based RFID systems and other high technology based tracking systems to provide end-to-end supply chain efficiencies, visibility and security with automated monitoring and decision support from command and control centers in North America, Europe and Asia to coordinate notification to shippers, customers and tactical responses among multiple agencies to interdict or respond to potential security threats. www.ISRsystems.com

About Shield Defense International

Shield Defense International (SDI), a wholly-owned subsidiary of Universal Guardian Holdings, Inc., designs and produces non-lethal weapons and systems that provide law enforcement, military, professional security and consumers with multiple use-of-force options to address appropriate threat conditions in today's growing global security and terrorist environments. www.ShieldDefense.com

About Secure Risks Limited

SecureRisks, a wholly owned subsidiary of Universal Guardian Holdings, Inc, is a London based global security group providing practical risk solutions, tactical security products and services, and critical infrastructure protection in today's most challenging environments from regional hubs located in the United States, United Kingdom, Europe, South America, Middle East, Africa, Central Asia and Asia Pacific. www.SecureRisks.com

Safe Harbor Statement:

This news release contains certain forward-looking statements pertaining to future anticipated projected plans, performance and developments, as well as other statements relating to future operations and results. Any statements in this news release that are not statements of historical fact may be considered to be forward-looking statements. Written words such as "may," "will," "expect," "believe," "anticipate," "estimate," "intends," "goal," "objective," "seek," "attempt," or variations of these or similar words, identify forward-looking statements. These statements by their nature are estimates of future results only and involve substantial risks and uncertainties, including those detailed from time to time in Universal Guardian Holdings, Inc.'s reports filed with the Securities and Exchange Commission. There can be no assurance that actual results will not differ materially from expectations. These risks factors include potential customer interest in the sale and production of Cobra StunLight(TM) and Riot Defender(TM) and their accessories.

Further information is available on the Company's website: www.UniversalGuardian.com

Investor Relations Contact:
Investor Relations
Universal Guardian Holdings, Inc.
4695 MacArthur Court, Suite 300
Newport Beach, CA USA 92626
+ 1 949. 861.8295 ext. 211

Company Contact:
Universal Guardian Holdings, Inc.
4695 MacArthur Court, Suite 300
Newport Beach, CA USA 92626
+ 1 949. 861.8295


SOURCE Universal Guardian Holdings, Inc.

Investor Relations, Universal Guardian Holdings, Inc., +1-949-861-8295, ext. 211, or
Michael J. Skellern, Chief Executive Officer of Universal Guardian Holdings, Inc.,
+1-949-861-8295

http://www.prnewswire.com


Copyright (C) 2005 PR Newswire. All rights reserved.

Bulldog's MiniBOSS Helps Foil Theft Ring

Dec 12, 2005 (financialwire.net via COMTEX) -- December 12, 2005 (FinancialWire) Bulldog Technologies Inc. (OTCBB: BLLD) reported that its MiniBOSS solution helped foil a theft ring involving $250,000 of designer clothing.

The Bulldog MiniBOSS is a cellular based true-AGPS covert asset recovery device, designed to work in conjunction with Bulldog's web-based software, allowing users to securely track their shipments using a standard PC. Since the MiniBOSS operates on an AGPS platform, its signal sensitivity is many times that of previous technologies. Additionally, the MiniBOSS can rely on both cellular tower triangulation and GPS satellite location to pinpoint the location of transportable materials throughout the United States, where cellular service is available.

Bulldog Technologies is receiving special Spotlight Analytics coverage in the Homeland Security Sector Report and quarterly Updates being produced by Investrend Research in partnership with Cronus Capital Markets and under the auspices of the Homeland Security Industry Association.

Investrend Research's unique and pioneering professional analyst program facilitates independent analysts to provide financial coverage for shareholders and investors in companies that otherwise would have little or no analyst following.

The Investrend Research program is the largest in the world and includes a number of safeguards to reduce or eliminate conflict. These systems, including media coverage and endorsements, may be accessed at http://www.investrendresearch.com

Investrend Research subscribes to the "Standards for Independent Research Providers" at http://www.firstresearchconsortium.com, and adheres to the Guidelines for independent providers jointly endorsed by the National Investor Relations Institute (http://www.niri.org) and the CFA Institute (http://www.cfainstitute.org) Buyside Magazine has stated that Investrend Research "remains in the vanguard of both standards and independence." ODwyerPR has cited Investrend Research as "exceeding the standards of CFAI-NIRI." The CFA Magazine, citing Investrend and its affiliates as having "strict rules about compensation and full disclosure," which "should go a long way towards ensuring objectivity," said "issuer-paid research is here to stay." Investrend has been cited by the Dow Jones Newswires, Financial Mail, Shareholder Value, and NIRI's "IR Update," which stated that Investrend "accomplishes the goal and more." Investrend's model has been endorsed by the New York Times, former SEC Chair Arthur Levitt and shareholders themselves, 70.9% of whom said in a survey at InvestoPedia, that a company that enrolls for "legitimate fee-based research is making a positive statement about its investment potential." A survey at Charles Schwab & Co. revealed that 78% of active shareholders now "value research from independent firms over analysts by Wall Street firms with financial ties to the companies they are rating."

Fees for "Spotlight Reports" are $4,000 per quarter, and the fees were paid by the company.

Complete information about any company enrolled in an Investrend shareholder empowerment platform, including those of its affiliates and independent analysts and webcasters, including disclosures and disclaimers, is available at the company's InvestorPower page at http://www.investrend.com/company/list.asp?sPathParam=yes, and on each report and press release, and investors are advised to read those disclosures carefully before trading in the equities of any enrolled company.

All independent sponsored research distributed by Investrend Research Syndicate are enrolled for investor-monitoring by the Shareholders Research Alliance at http://www.shareholdersresearch.com.

The Homeland Security sector coverage is being administered by Investrend Research analyst Ryan Fuhrmann, CFA. The analysts' credentials are at http://www.investrend.com/articles/secondlevel.asp?level=238

For more information about the sector report or "Spotlight Analytics" coverage, click on http://www.investrend.com/contact.asp or write contact@investrend.com

For up-to-the-minute news, features and links click on http://www.financialwire.net

FinancialWire is an independent, proprietary news service of Investrend Information, a division of Investrend Communications, Inc. It is not a press release service and receives no compensation for its news or opinions. Other divisions of Investrend, however, provide shareholder empowerment platforms such as forums, independent research and webcasting. For more information or to receive the FirstAlert daily summary of news, commentary, research reports, webcasts, events and conference calls, click on http://www.investrend.com/contact.asp

For a free annual report on a company mentioned in the news, please click on http://investrend.ar.wilink.com/?level=279

The FinancialWire NewsFeed is now available in multiple formats to your site or desktop, free. Click on: http://www.investrend.com/XmlFeeds?level=268


URL: http://www.financialwire.net

(C) 2005 financialwire.net, Inc. All rights reserved.

You mean like yesterday's 375,000 share lack of activity?
Sure looks to me like people getting in, not out.
------------------------------------------------------
H QUOTIENT INC - Nasdaq Other OTC: HQNT

Time & Sales most recent
Rec. Time Action Price Volume
3:58:08 PM Trade 0.22 10000
3:50:56 PM Trade 0.22 5000
3:50:50 PM Trade 0.2 5000
3:50:46 PM Trade 0.2 5000
3:49:10 PM Trade 0.2 10000
3:46:48 PM Trade 0.2 5000
3:45:40 PM Trade 0.2 10000
3:45:16 PM Trade 0.22 10000
3:43:58 PM Trade 0.2 2500
3:42:52 PM Trade 0.2 7500
3:42:24 PM Trade 0.22 10000
3:40:12 PM Trade 0.21 5000
3:40:08 PM Trade 0.22 10000
3:39:02 PM Trade 0.21 10000
3:38:38 PM Trade 0.21 7900
3:38:38 PM Trade 0.21 603
3:38:38 PM Trade 0.21 302
3:38:38 PM Trade 0.23 10000
3:33:58 PM Trade 0.2 10000
3:33:48 PM Trade 0.2 10000
3:32:24 PM Trade 0.2 10000
3:27:18 PM Trade 0.225 10000
3:27:12 PM Trade 0.23 10000
3:24:00 PM Trade 0.22 1000
3:24:00 PM Trade 0.22 10000
3:23:58 PM Trade 0.22 10000
3:22:14 PM Trade 0.2 10000
3:22:14 PM Trade 0.2 10000
3:22:04 PM Trade 0.18 20200
3:21:58 PM Trade 0.19 10000
3:17:16 PM Trade 0.19 10000
3:08:22 PM Trade 0.19 10000
2:59:12 PM Trade 0.17 7400
2:52:00 PM Trade 0.17 1847
2:43:58 PM Trade 0.17 520
1:29:30 PM Trade 0.17 15000
1:29:06 PM Trade 0.19 10000
1:25:46 PM Trade 0.16 509
1:25:02 PM Trade 0.18 20000
1:17:16 PM Trade 0.19 10000
12:53:42 PM Trade 0.19 5000
12:53:28 PM Trade 0.17 5000
12:36:24 PM Trade 0.15 3700
12:35:12 PM Trade 0.15 10000
12:35:08 PM Trade 0.17 10000
12:35:08 PM Trade 0.15 10000
11:48:44 AM Trade 0.17 2000

The market makers and the shorts will use every dirty trick they can to get ordinary shareholders to sell at the lows. It's pretty easy to beat them at this game - just don't sell at the lows (always the worst possible decision in any investment and the one they want you to make).

Bulldog's MiniBOSS(TM) Foils New Jersey Theft Ring Again -- New Jersey State Police are Impressed with Bulldog's Capability

RICHMOND, British Columbia, Dec 09, 2005 (BUSINESS WIRE) -- Bulldog Technologies Inc. ( BLLD ), premier international provider of real-time wireless security solutions and sensor networks that monitor, track and secure assets in the supply chain, today announced that the Bulldog MiniBOSS(TM) was again at the center of operations that followed a $250,000 shipment of designer clothing into the heart of a known fencing (buyer of stolen goods) ring. Caught in the reversal, the "Fence" was arrested on the spot and relieved of a substantial sum of cash, once again putting the Department's real-world stamp of approval on the Bulldog solution.

Sources close to the investigation remarked that the Bulldog System effectively levels the playing field for cargo owners, shippers and for law enforcement. "Traditionally and despite substantial information gathering and excellent police work, cargo disappearance has been a game of catch-up with police forces receiving notification hours, days and even weeks after events have occurred. The MiniBOSS(TM) enables proactive action to be taken in protecting shipments and apprehending those who are active in supply-chain theft".

Bulldog also intends to announce the outcome of two FBI sting operations in the near future. Additionally, Bulldog intends to announce the details of a special law enforcement program aimed at ongoing sting operations.

The Bulldog MiniBOSS(TM) is a cellular based true-AGPS covert asset recovery device. It is designed to work in conjunction with Bulldog's web-based software, allowing users to securely track their shipments using a standard PC. Since the MiniBOSS(TM) operates on an AGPS platform, its signal sensitivity is many times that of previous technologies. Additionally, the MiniBOSS(TM) can rely on both cellular tower triangulation and GPS satellite location to pinpoint the location of transportable materials throughout the United States, where cellular service is available.

About Bulldog Technologies

Bulldog Technologies Inc. researches, develops, and manufactures real-time, comprehensive monitoring, intrusion detection, covert asset recovery and tracking BOSS(TM) (Bulldog Online Security Solution) devices and solutions. Bulldog's Solutions allow dispatchers, security personnel, law enforcement/loss prevention professionals, emergency response teams and cargo transport drivers to monitor, track and secure valuable cargo during the transport, storage and delivery supply chain process. The Company serves an international clientele consisting of Governments, Law Enforcement, Large Enterprise, and Transportation.

For further information, visit Bulldog on the Web at http://www.bulldog-tech.com

SAFE HARBOR STATEMENT: This news release contains "forward-looking statements" that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward- looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "future", "plan" or "planned", "will" or "should", "expected", "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements, including the risks that our products may not achieve customer acceptance or that they will not perform as expected, that customer trials will not lead to future sales, and other risks identified in our annual report on Form 10-K and other filings with the SEC. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements are made as of the date hereof and Bulldog Technologies Inc. undertakes no obligation to update such statements.

SOURCE: Bulldog Technologies Inc.

Bulldog Technologies Inc.
Jan Roscovich, 604-271-8656 (Press Contact)
Email: jroscovich@bulldog-tech.com
or
Murray Schultz, 604-271-8656 (Investor Contact)
Email: mschultz@bulldog-tech.com


Copyright Business Wire 2005

IDSI CT Laser Mammography Results Shown at Major Radiological Meeting

FORT LAUDERDALE, Fla., Dec 08, 2005 /PRNewswire-FirstCall via COMTEX/ -- Imaging Diagnostic Systems, Inc. ( IMDS ) announced good commercial and clinical response to international clinical results shown at RSNA 2005, the 91st Scientific Assembly and Annual Meeting of the Radiological Society of North America. RSNA is IDSI's major event of the year, a forum in which to present clinical results, work-in-progress, and international commercial results to more than 60,000 attendees.

IDSI featured results from its exclusive CT Laser Mammography (CTLM(R)) scanner and highlighted its leadership in laser optical mammography technology by exhibiting select clinical cases from the more than 6,000 studies that have been completed worldwide.

"We presented cases from many of our luminary and partner sites, which showed CTLM results in the context of complete cases worked up with mammography, ultrasound, breast MRI, and biopsy results," explained Eric Milne, MD, FRCR, FRCP, IDSI Director of Clinical Research. "The comparisons were particularly useful to illustrate the adjunctive value of imaging the angiogenesis processes with passive CT laser technologies."

Tim Hansen, IDSI Chief Executive Officer, stated, "We were extremely pleased to have garnered such great interest in our revolutionary new modality and our approach to detecting and managing breast cancer. Our users presented compelling clinical results, our international distributors brought in attentive and interested prospects, and we received serious attention from university-level radiologists who are beginning to understand the key role CTLM may play in multimodality breast cancer case management."

Commented Dr. Milne, "The acceptance of our non-invasive optical method of detecting angiogenesis in breast cancer, which we have been developing and promulgating for close to ten years, has been confirmed at this year's RSNA meeting by the virtual 'explosion' in technical developments of MRI of the breast, designed to image angiogenesis, and in the many papers presented on angiogenesis in breast cancer."

IDSI also received international media attention, providing interviews to German and American publications as well as Australian television.

The CTLM(R) system is the first patented breast imaging system that utilizes state-of-the-art laser technology and patented algorithms to create 3-D cross-sectional images of the breast. It is a non-invasive, painless examination that does not expose the patient to radiation or require breast compression. Imaging Diagnostic Systems has received CE Marking, CMDCAS (Canada), Canadian License, China SFDA approval, UL listing, ISO 9001:2000- 13488 certification and FDA export certification for its CT Laser Breast Imaging system. The Company is seeking PreMarket Approval (PMA) from the Food and Drug Administration (FDA) for its CTLM(R) system to be used as an adjunct to mammography.

Please visit Imaging Diagnostic Systems' website at: http://www.imds.com for additional information.

In conjunction with the provisions of the Safe Harbor section of the Private Securities Litigation Reform Act of 1995, this news release may contain forward-looking statements pertaining to future anticipated projected plans, performances and developments, as well as other statements relating to future operations. All such forward-looking statements are necessarily only estimates of future results and there can be no assurance that actual results will not materially differ from expectation. Further information on potential factors that could affect Imaging Diagnostic Systems, Inc. is included in the Company's filing with the Securities Exchange Commission.

Investor Relations:
Rick Lutz
404-261-1196
lcgroup@mindspring.com


SOURCE Imaging Diagnostic Systems, Inc.

Investor Relations, Rick Lutz, +1-404-261-1196, or lcgroup@mindspring.com, for
Imaging Diagnostic Systems, Inc.

http://www.prnewswire.com


Copyright (C) 2005 PR Newswire. All rights reserved.

US Financial Network: Healthnostics Launches Post-Genomics Blog for MedBioWorld and Nursing Home Quality Stagnates, Says HealthGrades

Dec 07, 2005 (M2 PRESSWIRE via COMTEX) -- City of Industry, CA - Healthcare Information Services industry news provided by Financial News USA (OTC: FNWU) Healthnostics, Inc. (OTC: HNST), a clinical information system and medical and bioscience informatics company, recently announced the launch of Post-Genomics, the new blog from Healthnostics' portal, MedBioWorld (http://www.MedBioWorld.com). Written by eminent scientists and researchers in the post-genomics fields, the Post-Genomics blog is the first resource of its kind that aims to facilitate a connection between the theoretical, research-based work in post-genomics and the clinical side of its application.

Affiliated Computer Services, Inc. (NYSE: ACS), a premier provider of business process outsourcing and information technology solutions, announced today that it has formed an alliance with Microsoft to provide development and marketing resources to deliver its fire department records management system, ACS FIREHOUSE Software , on the Microsoft .NET platform. Nursing home deficiencies causing actual harm to residents declined from 7.0 percent to 6.5 percent from 2003 to 2004, while patient abuse remained stable at 17 percent of complaints, according to a new analysis of the ratings HealthGrades (Nasdaq: HGRD) annually gives to nearly every nursing home in the country. Overall, the deficiencies cited per nursing home declined 2.0 percent from 2003 and 2004, the analysis found. Emdeon Corporation (Nasdaq: HLTH) announced recently that it will commence a tender offer next week to purchase up to 60,000,000 shares of its common stock at a price per share of $8.20. The number of shares proposed to be purchased in the tender offer represents approximately 17.4% of the Company's currently outstanding shares. The Company will use its cash on hand for the purchase. The last reported sales price per share of the Company's common stock on the Nasdaq National Market on Thursday, November 17, 2005 was $8.37 per share.

About Financial News USA

Financial News USA is a Next Generation Financial Communications firm focused on the distribution of market moving news. Financial News USA has developed leading edge e-publishing tools including programming proprietary RSS feeds and enabling open source press release publishing across its network. Financial News USA has been aggressively expanding its news distribution network by targeting direct feeds to financial news and data providers such as FinancialContent, Yahoo (NASDAQ: YHOO), among others. Financial News USA offers a free news feed available online (www.financialnewsusa.com) to websites and financial services looking for content and for individual investors looking to stay informed on the financial markets. Financial News USA and its affiliates charge each client cash for news distribution and may take an equity position in the companies mentioned herein, please visit the disclaimer at www.financialnewsusa.com

CONTACT: Financial News USA Tel: +1 626 961 8041 e-mail: info@financialnewsusa.com

M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.


(C)1994-2005 M2 COMMUNICATIONS LTD

**********************************************************************
As of Saturday, 12-03-2005 23:59, the latest Comtex SmarTrend(SM) Alert, an automated pattern recognition system, indicated an UPTREND on 10-21-2005 for ACS @ $52.41.

As of Saturday, 12-03-2005 23:59, the latest Comtex SmarTrend(SM) Alert, an automated pattern recognition system, indicated a DOWNTREND on 10-07-2005 for HLTH @ $10.49.

(C) 2005 Comtex News Network, Inc. All rights reserved.

-0-

Bulldog Technologies Inc. -- Product Update from the President

RICHMOND, British Columbia, Dec 07, 2005 (BUSINESS WIRE) -- Bulldog Technologies Inc. ( BLLD ) -- From observing inquiries from investors, it has become apparent that Bulldog Technologies' achievements need to be better understood and as President and CEO, I would like to outline these achievements and draw attention to Bulldog's accomplishments.

Bulldog has truly developed some of the most unique solutions for the cargo industry through using the latest technologies available. During the last ten years companies like Qualcomm have marketed tracking systems for trucks and tractor trailers but have been unable to address the real underlying problem -- security.

Bulldog's latest road unit, the RoadBOSS(TM) GTS, can now secure the cargo door from the outside of the container without breaking the seal. Using Bulldog's web-based software the customer can monitor movement of the truck and trailer in real-time, from point of departure to point of arrival, from their dispatch centre. This is achieved by housing a state of the art GSM/satellite electronics module and military specification energy pack inside the RoadBOSS(TM) GTS. In addition to precision satellite tracking, the GTS unit monitors door openings, vibrational and tilting movement of the trailer when parked, starting and stopping motion among other security based criteria.

The MiniBOSS(TM) allows the tracking of goods or parcels from inside the trailer, allowing a shipper to locate the parcel en route or as soon as it has gone missing. This is done by placing the Unit directly inside a pallet load of goods or parcel. The MiniBOSS(TM) houses assisted GPS technology, allowing it to get its position through GPS satellite and cell tower triangulation. Unlike regular GPS, the proprietary MiniBOSS(TM) technology allows the Unit to receive signals from inside trailers, warehouses and even concrete structures and will give accurate positioning to within twenty meters.

During the seven years that Bulldog has invested in the development of its products, the Company has worked closely with operators of container ports, trucking companies and manufacturing companies. It has become apparent that until Bulldog's arrival, these customers were not able to find adequate cargo security solutions. With Bulldog's BOSS(TM) products, however, not only can these companies track their cargo, they can also track their vehicle all for one low cost. Imagine having a tractor trailer loaded with pallets of expensive goods and then randomly placing hidden tracking devices amongst those pallets. Then imagine that a pallet, a box or even the whole trailer is stolen and you have the ability to track your goods directly to wherever they may have been transported. Whether underground or placed into another container, the stolen goods are able to be located within minutes. In addition, imagine being able to track perishable goods; whether it is produce, dairy or frozen foods, and being able to track the vehicle and protect the goods from being stolen while also monitoring the temperature to ensure stability. This is precisely what Bulldog Technologies Inc. has developed and is the reason for global inquiries from a list of Fortune 50, 100 and 500 companies.

The Company's first three sales were with Fortune 500 companies. Did these companies evaluate other systems prior to installing Bulldog's products? This should be a major indication to not only Bulldog stakeholders and investors but for other customers that do not have the time or money with which to evaluate the many and varied solutions.

Security can be a very delicate issue with Fortune 500 companies and Bulldog is in agreement to not broadcast the fact that the customer has placed security devices within their shipments. Bulldog will mention, however, that a purchase order has been received. In most cases there is an implementation period of two to four weeks to incorporate the security device into a customer's organization. This allows the customer to identify logistics of device management. Bulldog's software has been designed to implement the products in a relatively short period of time.

The MiniBOSS(TM), RoadBOSS(TM) and TankerBOSS(TM) have an airtime residual. As an example: 10,000 MiniBOSS(TM) units would generate up to $500,000 per/month. Add this figure to airtime revenues generated by RoadBOSS(TM) and TankerBOSS(TM) units and the figures are encouraging.

To gage industry reception of Bulldog's BOSS(TM) products, it is important to know that a growing list of insurance companies is providing premium discounts to Bulldog's customers. Moreover, these discounts are substantial and ongoing; effectively paying for the purchase of Bulldog products in short order and letting the customer garner ongoing savings. Bulldog's BOSS(TM) products will become a strong deterrent to perpetrators of cargo loss thereby saving not only money but the irreplaceable asset -- time.

It is important to note that all Bulldog developments are under patent protection. This is also why Kyocera Corp. (the world's largest producer of wireless electronics) has nominated Bulldog for a technology award and sees the company as having achieved a technology and marketing triumph.

Going forward, the success of Bulldog is tied, in part, to being first to market with these technologies. Not only has Bulldog achieved this "first to market" advantage, it has also been able to produce its leading edge security and tracking solutions at price points that are extremely attractive to customers. In addition to internal sales and marketing success, a continuous stream of independent enquiries for Bulldog's products indicates that the Company is on the fast and right track.

I thank you for your continued support.

John Cockburn

President and CEO

For further information, visit Bulldog on the Web at http://www.bulldog-tech.com.

Safe Harbor Statement: This news release contains "forward-looking statements" that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "future", "plan" or "planned", "will" or "should", "expected", "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements, including the risks that our products may not achieve customer acceptance or that they will not perform as expected, that customer trials will not lead to future sales, and other risks identified in our annual report on Form 10-K and other filings with the SEC. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements are made as of the date hereof and Bulldog Technologies Inc. undertakes no obligation to update such statements.

SOURCE: Bulldog Technologies Inc.

Bulldog Technologies Inc.
Jan Roscovich, 604-271-8656 (Press Contact)
jroscovich@bulldog-tech.com
or
Murray Schultz, 604-271-8656 (Investor Contact)
mschultz@bulldog-tech.com


Copyright Business Wire 2005

Healthnostics Launches Post-Genomics Blog for MedBioWorld

BETHESDA, MD, Dec 06, 2005 (MARKET WIRE via COMTEX) -- Healthnostics, Inc. (OTC: HNST), a clinical information system and medical and bioscience informatics company, today announced the launch of Post-Genomics, the new blog from Healthnostics' portal, MedBioWorld (http://www.MedBioWorld.com). Written by eminent scientists and researchers in the post-genomics fields, the Post-Genomics blog is the first resource of its kind that aims to facilitate a connection between the theoretical, research-based work in post-genomics and the clinical side of its application.

The pieces on MedBioWorld's Post-Genomics blog are authoritative, timely, informative and conversational in tone. They focus on different aspects of the post-genomics area of study--from defining and explaining the derivations of genomics,' such as glycomics and lipidomics, to describing efforts for establishing standards in these areas, to raising concerns that perhaps were overlooked in the excitement of new developments. Both bioscience researchers and medical professionals who are not intimately familiar with current work in this field but who are now encountering its application in their offices and hospitals will benefit from MedBioWorld's Post-Genomics blog.

"The scientists and researchers contributing to this post-genomics blog are of the highest caliber," said Alexa Hackbarth, creative director of Healthnostics, Inc. "We're very excited about the dialogue and discussions this blog will evoke among our professional MedBioWorld user community.''

Further information concerning becoming a contributor can be found on the blog's site under "Become a Contributor" (http://www.MedBioWorld.com/postgenomics_blog).

About Healthnostics

Healthnostics, Inc. is a clinical information system and medical and bioscience informatics company. Healthnostics provides comprehensive patient clinical monitoring and risk reduction systems to acute care hospitals and utilizes its Internet portals to deliver healthcare and bioscience information to its hospital clients, industry professionals and the general public. Healthnostics products include MedGuardian (http://www.med-guardian.com), a patient care monitoring and risk management system for hospitals that's fully Web-based; MedBioWorld(TM) (http://www.medbioworld.com/), the largest professional medical and bioscience directory resource and reference portal site on the Internet; and, FamilyMedicalNet (http://www.familymedicalnet.com/), a companion consumer healthcare information portal.

For further information please visit Healthnostics www.healthnostics.com, MedGuardian www.med-guardian.com, MedBioWorld www.medbioworld.com, and FamilyMedicalNet www.familymedicalnet.com.

This announcement may contain, in addition to historical information, certain forward-looking statements that involve risks and uncertainties. Such statements reflect management's current views and are based on certain assumptions. Actual results could differ materially from the assumptions currently anticipated.



Contacts:
Jason Pollack
561-731-2215

Stuart T. Smith
P. 512-267-2430
F. 512-267-2530
SSmith@SmallCapVoice.com www.SmallCapVoice.com

SOURCE: Healthnostics, Inc.



CONTACT: mailto:SSmith@SmallCapVoice.com
http://www.SmallCapVoice.com


Copyright 2005 Market Wire, All rights reserved.

-0-

SUBJECT CODE: Medical and Healthcare:Facilities and Providers
Medical and Healthcare:Healthcare
Computers and Software:Networking

CEL-SCI Answers Questions Regarding Testing Agreement With NIH for Drug Against Avian Flu Virus H5N1

VIENNA, Va., Dec 06, 2005 /PRNewswire-FirstCall via COMTEX/ -- On December 5, 2005, CEL-SCI CORPORATION ( CVM ) announced that it had signed a Cooperative Agreement with the National Institute of Allergy and Infectious Diseases (NIAID), an institute of the National Institutes of Health of the U.S. government, to test CEL-SCI's patented anti-infective drug CEL-1000 against the avian (bird) flu virus H5N1 in animal models. The testing will be conducted to determine whether CEL-1000 could be used as a potential treatment and/or preventive agent against this virus.

The December 5th release has resulted in a number of questions from shareholders and the media. Since the questions are fairly uniform, CEL-SCI will attempt to answer them in this release.

1) Who will pay for the tests? The NIH will pay for the tests.
2) If the tests are successful, what will come next? That determination
will be made at that point in time and is not covered by the current
agreement.
3) Will supply of CEL-1000 delay the testing? No, CEL-SCI currently has
adequate amounts of CEL-1000 available for testing.
4) Is manufacturing of this product for the tests and/or potential sale of
the product a problem? No, we have CEL-1000 on hand to do the current
testing. CEL-1000 is produced for CEL-SCI by contract manufacturers.
There are several capable contract manufacturers who could produce and
formulate CEL-1000 into a drug product that meets all of the required
regulations.
5) You state that CEL-1000 is related to your L.E.A.P.S.(TM) technology
which requires a different antigen for each disease. Does CEL-1000
require the avian flu antigen? No, the great attraction of CEL-1000 in
this case is that it has previously been shown to protect animals
against viruses and unrelated diseases without a specific antigen. In
all of these tests, the same peptide was used. It is this lack of
specificity that makes CEL-1000 such an attractive potential therapy
against the changing avian flu virus.
6) How do you envision that your product could potentially be used against
the avian flu? We envision three potential applications. One, as a
preventive, since CEL-1000 was shown to be 100% protective in animal
challenge studies against viruses and unrelated diseases. Two, as a
treatment. Three, as an adjuvant to enhance the immune response to the
current avian flu vaccine being made. There is a clear need to reduce
the amount of antigen required for an immune response per person since
the current facilities cannot produce anywhere close to the amount of
vaccine required. The addition of an adjuvant to the vaccine should
allow for a larger number of vaccine doses with the same amount of
antigen which would expand substantially the number of persons who
could be vaccinated with a protective dose.
7) Why do you think that CEL-1000 might work against the avian flu virus?
CEL-1000 appears to activate innate (very early stage) and Th1 type
(cellular) immune responses to induce a broad-spectrum protection
against infection in animal models. The innate immune system is
generally accepted to be the first line of defense against infectious
agents. We believe that activating innate immunity might also help
against the avian flu virus.

CEL-1000, derived from the beta chain of human MHC-II, is a modified version of a human immune-based protein known to bind to both human and mouse immune cells and appears to act by enhancing the host's protective immune response.

The National Institutes of Health (NIH) -- The Nation's Medical Research Agency -- includes 27 Institutes and Centers and is a component of the U. S. Department of Health and Human Services. It is the primary Federal agency for conducting and supporting basic, clinical, and translational medical research, and it investigates the causes, treatments, and cures for both common and rare diseases.

CEL-SCI Corporation is developing new immune system based treatments for cancer and infectious diseases. The Company has operations in Vienna, Virginia and Baltimore, Maryland.

When used in this report, the words "intends," "believes," "anticipated" and "expects" and similar expressions are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties which could cause actual results to differ materially from those projected. Factors that could cause or contribute to such differences include, an inability to duplicate the clinical results demonstrated in clinical studies, timely development of any potential products that can be shown to be safe and effective, receiving necessary regulatory approvals, difficulties in manufacturing any of the Company's potential products, inability to raise the necessary capital and the risk factors set forth from time to time in CEL-SCI Corporation's SEC filings, including but not limited to its report on Form 10- K for the year ended September 30, 2004. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

SOURCE CEL-SCI Corporation

Gavin de Windt of CEL-SCI Corporation, +1-703-506-9460; Investor Relations, Mike
Lucci of Lucci Financial Group, LLC, +1-248-723-3330

CEL-SCI Signs Agreement With U.S. Government Institute for Testing of Drug Against Avian Flu Virus H5N1

VIENNA, Va., Dec 05, 2005 /PRNewswire-FirstCall via COMTEX/ -- CEL-SCI CORPORATION ( CVM ) has signed a Cooperative Agreement with the National Institute of Allergy and Infectious Diseases (NIAID), an institute of the National Institutes of Health of the U.S. government, to test CEL-SCI's patented anti- infective drug CEL-1000 against the avian (bird) flu virus H5N1 in animal models. The testing will be conducted to determine whether CEL-1000 could be used as a potential treatment and/or preventive agent against this virus.

CEL-1000 has previously been shown to be protective in animal challenge studies against viruses and unrelated diseases, specifically herpes simplex virus, viral encephalitis and malaria, and to enhance survival against cancer in animals. CEL-1000 appears to activate innate (very early stage) and Th1 type (cellular) immune responses to induce a broad-spectrum protection against infection in animal models. The innate immune system is generally accepted to be the first line of defense against infectious agents.

Geert Kersten, Chief Executive Officer of CEL-SCI said, "CEL-1000 has been successfully tested in a number of diseases with the support of the U.S. government. We hope that CEL-1000 can activate the immune system to successfully defeat the avian flu virus as it has done against other viruses."

CEL-1000, derived from the beta chain of human MHC-II, is a modified version of a human immune-based protein known to bind to both human and mouse immune cells and appears to act by enhancing the host's protective immune response.

The National Institutes of Health (NIH) -- The Nation's Medical Research Agency -- includes 27 Institutes and Centers and is a component of the U. S. Department of Health and Human Services. It is the primary Federal agency for conducting and supporting basic, clinical, and translational medical research, and it investigates the causes, treatments, and cures for both common and rare diseases.

CEL-SCI Corporation is developing new immune system based treatments for cancer and infectious diseases. The Company has operations in Vienna, Virginia and Baltimore, Maryland.

When used in this report, the words "intends," "believes," "anticipated" and "expects" and similar expressions are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties which could cause actual results to differ materially from those projected. Factors that could cause or contribute to such differences include, an inability to duplicate the clinical results demonstrated in clinical studies, timely development of any potential products that can be shown to be safe and effective, receiving necessary regulatory approvals, difficulties in manufacturing any of the Company's potential products, inability to raise the necessary capital and the risk factors set forth from time to time in CEL-SCI Corporation's SEC filings, including but not limited to its report on Form 10- K for the year ended September 30, 2004. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

SOURCE CEL-SCI Corporation

Gavin de Windt of CEL-SCI Corporation, +1-703-506-9460 or Investor Relations: Mike
Lucci of Lucci Financial Group, LLC, +1-248-723-3330, for CEL-SCI Corporation

http://www.prnewswire.com


Copyright (C) 2005 PR Newswire. All rights reserved.

This week's PR does specify that the dividend distribution is expected to take place THIS month...

"...the Company expects to distribute one share of SNDH for every two shares of HQNT stock. The finalization of this dividend will be announced along with the record date. The shares will be restricted for two years or until a registration is filed. This transaction is expected to take place during December 2005."

Very Positive Article on VASO's EECP Tech this week...
---------------------------------------------------------
Doctors can't say why it works, but some patients swear by the results.

Robyn Shelton | Sentinel Medical Writer
Posted November 29, 2005

Doctors have cut into Theodore Dippy's heart twice to clear clogged arteries. Other times, they swept aside blockages with tiny balloons and once left a metal stent inside an artery to keep it propped open.
After going through the most common heart procedures available, the Lake County man finally found relief with a little-known treatment that involves squeezing the legs in large cuffs to propel more blood to the heart.
The nonsurgical approach, called Enhanced External Counterpulsation, is viewed with disdain by some cardiologists who question its value because researchers can't say exactly how it helps the heart.
But studies have found that most patients who undergo the treatment have a significant reduction in the chest pain that otherwise might keep them from walking up a flight of stairs or even across the front yard.
"I would say about three-quarters of patients get some benefit from it," says Dr. Andrew Michaels, who has been involved in research on the technique at the University of California at San Francisco. "Most patients can exercise further and have improved quality of life.
"On the negative side, we still don't have a clear understanding of why it works."
The low-tech treatment is carried out during one-hour sessions while the patient lies on a padded table with three large cuffs on each leg -- positioned on the calves, lower thighs and upper thighs.
The cuffs squeeze sequentially up the leg with enough force to jerk the person upward slightly. They only inflate when the heart is not beating, in the moment of rest between each contraction. This is why the treatment is called "counterpulsation."
Patients typically undergo 35 sessions spread across seven weeks, with five treatments per week. And some people require more sessions before they see improvement.
Dippy, 80, says he needs 45 sessions to get relief from his chest pain, or angina, which afflicts an estimated 6.4 million Americans.
He has gone through seven courses of the treatment since 1999. No longer a candidate for surgical procedures, Dippy says he relies on the therapy to keep his heart from further deterioration.
"Whenever my angina starts to get worse, I go in for another dose," Dippy says. "I've gotten to the point where I am pretty familiar with my heart. I know when it needs it."
Method dates to 1950s
Dippy's doctor, cardiologist Ken Kronhaus in Mount Dora, has treated more than 600 patients with Enhanced External Counterpulsation, called EECP for short.
Kronhaus says the therapy dates back to the 1950s, when doctors at Harvard University began experimenting with a water-powered machine to increase pressure on the legs and drive more blood toward the heart. It wasn't successful.
"All this big, hydraulic device did was crimp and crush the legs, and they kind of gave up on it," Kronhaus says.
Decades later, in the 1980s, scientists in both the United States and China began tinkering with the approach again. But it was the Chinese who really ran with it, refining the technology and using it extensively to treat patients in the 1990s.
In the United States, interest grew in the idea after trials began to show potential benefits.
One 1999 study of 5,000 patients worldwide found that 73 percent of those treated had a significant reduction in their angina. What's more, the patients still were enjoying the improvements two years later.

Today, doctors throughout Florida offer the treatments, and prestigious medical centers, including the Mayo Clinic and the Cleveland Clinic, have centers for the procedure.
How does it work?
But the underlying question remains: How does the procedure benefit the heart?
Kronhaus says doctors think the rush of blood from the lower body stimulates hormones and helps create new, tiny vessels in the heart that improve blood flow.
"We all have these hormones, but what this procedure does is enhance the flow back to the heart, increasing the concentration of hormones and stimulating new vessel growth," he says. "It's like growing new branches on the trunk of a tree."
Researchers have been able to document the improved blood flow by doing heart scans on patients before and after treatment to look for changes. Kronhaus says the procedure can nurture new vessel development up to six months after the sessions end.
Despite growing acceptance, the procedure remains a last-resort treatment, only after surgery or other invasive procedures have been deemed too risky.
Medicare began paying for the procedure in 1999, but only when it's used on severe angina patients who have no other options. Other insurers also cover the procedure, which can cost $5,000 to $7,000, for patients in this category. Kronhaus thinks the therapy's image as a last resort keeps it from being used more widely.
Still not widely known
Many doctors, even cardiologists, still have not heard of the treatment.
"I think the main reason stems from a lack of a clear mechanism of benefit," says Michaels, who has worked as a consultant for the company that makes the technology for the procedure, Vasomedical. "It's hard for people to understand why squeezing the legs for 35 hours would reduce angina over the long term."
The American College of Cardiology and the American Heart Association, which jointly issue treatment guidelines for doctors, gave the procedure a lukewarm rating in 2002, saying its usefulness and efficacy are not well-established.
But more studies have been finished in recent years, including one just released in March that showed the treatment also can benefit patients with congestive heart failure. Those who were treated increased their exercise time on a treadmill by about 25 seconds, while time decreased by about 13 seconds in a similar group of patients who did not undergo the therapy.
Doctors who offer the therapy see a trend toward its greater use.
"It doesn't work for everyone, but when it works, it works," says Dr. Arnold Einhorn, a cardiologist with Orlando Regional Medical Center. "I've had people who've had a dramatic improvement in their quality of life."
As a physician himself, Dippy says he approached the therapy with skepticism. But now he knows firsthand how a round of the procedure can reduce his chest pain and help him remain active.
"It works well for me," he says. "It's a whole lot better than surgery and a whole lot better than angina."

Robyn Shelton can be reached at rshelton@orlandosentinel.com or 407-420-5487.

Great to hear. I first found out about INCA when it was recommended by The Cheap Investor newsletter earlier this year. The Cheap Investor also does not accept any compensation for their profiles and recommendations. Here is the link to their site:
http://www.thecheapinvestor.com

Note: This is a print published newsletter covering low priced stocks. The actual newsletter is not on the site above, just information about it and how to contact the publishers. They do offer one free issue to anyone who requests it. If you check the C.I. track record you will note that they are the best in their sector and were recently rated #1 in a 2 year independent study (details on site above).

Market Gainer Releases Profile for Bulldog Technologies Incorporated

Nov 30, 2005 (M2 PRESSWIRE via COMTEX) -- MarketGainer.com strives to find dynamic issues that are unknown but because of their technology, approach, executive team, recent discoveries or other key factors, could advance in the market. MarketGainer.com has identified the following company based on these criteria.

Bulldog Technologies Incorporated (OTCBB: BLLD), a company that develops and manufactures real-time wireless security solutions and sensor networks. The Company serves an international clientele consisting of Governments, Law Enforcement, Large Enterprise and the Transportation and Storage Sectors, among others.

Bulldog Technologies is having a respectable day in the market up 5 percent with over 193 000 shares traded, well above the average volume of 93 000 shares. Over the last 3 months the share price for the Company has been jumping back and forth between $.90 and $1.00. There was an upward spike in the share price at the beginning of October as it went to about $1.20. More recently, the Company's share price grew some legs in the middle of November and has run up to over $1.40 in the last two weeks. At the present time, the price of the Company's shares is positioned at $1.46, which is an increase of 7 cents on the day.

The rise in investor interest towards the Company today is a result of Bulldog Technologies Inc. announcing this morning that yet another undisclosed "Fortune 500" company specializing in grocery food products has issued their first purchase order for the Bulldog MiniBOSS(TM) covert tracking and loss-prevention solution. Bulldog is honoring the customer's request for anonymity to preserve the integrity of their DLR (Deter-Locate-Recover) operations.

The international multi billion dollar company has selected the Bulldog MiniBOSS(TM) covert tracking and loss-prevention solution after they completed their due diligence in the decision process. The undisclosed company will be using the tracking system to keep tabs on and protect their goods in the transit. When the initial stage is finished, the company will intends to expand the system to cover all goods in their supply chain.

As a brief description of the Bulldog technology in question, the MiniBOSS(TM) System provides an advanced facility to secure, track and recover product shipments and also advances the company's cost savings model while providing...........

To view the full Market Gainer report on Bulldog Technologies Incorporated, please visit www.marketgainer.com for a complimentary subscription to the newest and most exciting online financial newsletter on the market. No Credit Card information needed.

The Financial Information and Financial Content provided by Marketgainer.com is for informational purposes only and should not be used or construed as an offer to sell, a solicitation of an offer to buy, or endorsement, recommendations, or sponsorship of any company or security by Marketgainer.com. You acknowledge and agree that any request for information is unsolicited and shall neither constitute nor be construed as investment advice by Marketgainer.com to you. It is strongly recommended that you seek outside advice from a qualified securities professional prior to making any securities investment. Marketgainer.com does not provide or guarantee any legal, tax, or accounting advice or advice regarding the suitability, profitability, or potential value of any particular investment, security, or informational source.

All material herein was prepared by based upon information believed to be reliable. The information contained herein is not guaranteed by Market Gainer to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Market Gainer is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission.

M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web Inquiries to info@m2.com.


(C)1994-2005 M2 COMMUNICATIONS LTD

To stop your shares from being loaned out to shorts, put in a high GTC sell order on all your shares (above .02 here at least). You may also be able to give a written instruction to your broker that none of your shares in any stocks you own are to be loaned out for shorting. Additionally, requesting your shares in certificate form will also take them away from the shorts' reach. All real shareholders should take some action to stop the short sellers from robbing our investment value.

The Bellwether Report has identified HealtheUniverse Inc. (OTC:HLUN) and Aastrom Biosciences, Inc. (NADAQ:ASTM), as two undervalued companies

Dec 01, 2005 (M2 PRESSWIRE via COMTEX) -- Today the Bellwether Report has identified HealtheUniverse Inc. ( HLUN ) and Aastrom Biosciences, Inc. (NADAQ:ASTM), two explosive companies that our analysts will be keeping a close watch on over the next 30 days as they have came out with significant corporate developments this morning.

Healtheuniverse Inc. ( HLUN ), a biotechnology development firm specializing in the development and commercialization of biopharmaceutical and biomedical products, announced today that CEO Vipul Dev, MD and his scientific team have reached the research and development stage of various applications of growth factors, progenitor cell lines, and dressings that promote accelerated wound healing with decreased scarring.

Normal wound repair has been thought to involve the proliferation and migration of local terminally differentiated cell types into the wound from adjacent uninjured tissue. However, recent evidence suggests that coetaneous repair also involves recruitment of non-resident, undifferentiated cells from distant sources, such as fat cells. Populations of progenitor cells have been identified as valuable sources of uncommitted cells that are capable of reconstituting multiple cell types in various tissues, including skin. This population of cells may play a critical role in the induction of tissue regeneration at sites of injury. The ability to manipulate these cells may provide a previously unrecognized means of therapeutic intervention in patients and is the focus of Healtheuniverse research.

"We have achieved several key objectives on research advancement and corporate development," stated Dr. Vipul Dev, MD Chief Executive Officer of Healtheuniverse, Inc. "Foremost, we have aligned the Company's focus on the development of proprietary technoligies, and are now concentrated on a key business area, living wound healing products and bioengineered surgical products."

Bellwether Report was the first to bring its subscribers this small cap Hidden Gem!! HealtheUniverse Inc. traded up over 20% from its open yesterday on extremely strong volume (1.6 million shares). Bellwether Report believes that if HealtheUniverse Inc. can continue this solid business plan and put it into action they should continue to see success.

Aastrom Biosciences, Inc. ( ASTM ) today yesterday it will initiate a human clinical trial for the evaluation of the Company's Tissue Repair Cell (TRC) product to form new bone tissue in the spine. The Phase I/II trial will be conducted under an Investigational New Drug (IND) application approved by the U.S. Food and Drug Administration (FDA), and initially conducted at a single clinical center, the William Beaumont Hospital in Royal Oak, MI (Beaumont Hospital). Aastrom's TRCs, a proprietary bone marrow-derived adult stem cell product, will be used in posterior-lateral lumbar spinal fusions for treatment of degenerative spondylolisthesis. This is the Company's second FDA-approved, human clinical trial for local bone regeneration using TRCs.

This spine fusion clinical trial will be conducted under the direction of Principal Investigator Harry Herkowitz, M.D., Department Chair of Orthopedic Surgery at Beaumont Hospital. Spine fusion is a procedure in which new bone tissue is induced to fuse two or more vertebrae together to treat conditions such as fractures of the vertebrae, or ruptured or lost disks. Current therapy uses surgically transplanted bone tissue, as well as other artificial bone materials and bone growth factors, to induce the growth of new bone tissue. Aastrom proposes to use its TRCs in combination with a carrier matrix to induce sufficient bone growth to fuse or merge two vertebrae in the lower back, and potentially eliminate the requirement for other more invasive or less effective approaches. By stabilizing the spine, this procedure reduces debilitating back pain, and helps a patient regain more normal use of their legs. The primary purpose of this approved clinical trial is to confirm that Aastrom's TRC product, when used as a bone graft, is safe for use in posterior-lateral lumbar spinal fusion surgery, and is able to generate new bone at the fusion site, based on defined radiographic and clinical data.

Aastom Biosciences Inc traded up over 6% yesterday on more than 3 times its average volume following this announcement.

The Bellwether analysts will be tracking the day's events with both of these companies to see how the markets react. Our research of each company will continue over the next 30 days to gauge the impact of these events.

If you would like to receive all corporate updates on the companies feel free to visit, www.bellwetherreport.com.

The Bellwether Report is proud to announce the newest component of our website www.bellwetherreport.com. The "Pre Bell Alerts" has been activated, these are indications on companies that we will be tracking, as our analysts believe that their announcements just before the markets closed, could significantly impact trading on the next day.

The Bellwether Report, will continue scanning the markets for true emerging growth opportunities that will show subscribers optimal entry points with profitable exit points. If you are interested in receiving more information on the above mentioned companies feel free to sign up for a 1 month complimentary subscription to the #1 online investment resource www.bellwetherreport.com.

All material herein was prepared by the Bellwetherreport.com , (Bellwether) based upon information believed to be reliable. The information contained herein is not guaranteed by Bellwether to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion.

This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Bellwether is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. Bellwether may receive compensation in cash or shares from independent third parties or from the companies mentioned.

Bellwether's affiliates, officers, directors and employees may also have bought or may buy the shares discussed in this opinion and may profit in the event those shares rise in value. Market commentary provided by Jay Lee.

Bellwether will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission.

You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and Bellwether undertakes no obligation to update such statements.

To view the Full Disclaimer please feel free to visit www.bellwetherreport.com and visit the disclaimer section found at the bottom of the main members page.

M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.

(C)1994-2005 M2 COMMUNICATIONS LTD

H-Quotient Updates Significant Events

VIENNA, VA--(MARKET WIRE)--Nov 30, 2005 -- H-Quotient, Inc. (Other OTC:HQNT.PK - News) -- On October 25, the Company announced completion of negotiations to sell its medical manufacturing subsidiary, Stewart & Shaw Inc., to Standard Holdings Group Ltd. (Other OTC:SNDH.PK - News). That transaction is now being finalized and from the consideration received, the Company expects to distribute one share of SNDH for every two shares of HQNT stock. The finalization of this dividend will be announced along with the record date. The shares will be restricted for two years or until a registration is filed. This transaction is expected to take place during December 2005.

HQNT management changes are being contemplated as the Company seeks to expand its core medical software business and complete its prior years' audited financial statements.

This announcement may contain, in addition to historical information, certain forward-looking statements that involve risks and uncertainties. There is no assurance that this transaction will be completed. Such statements reflect management's current views and are based on certain assumptions. Actual results could differ materially from the assumptions currently anticipated.

For more information visit the H-Quotient web site at http://www.hquotient.com.

Contact:
H-Quotient, Inc.
(703) 821-3434

------------------------------------------------
Source: H-Quotient, Inc.

This is a very large dividend for HQNT shareholders (a 50% dividend). It is the largest dividend the company has announced to date. Also, keep in mind that HQNT shorts will be liable to PAY this dividend instead of receiving it. And note that the qualification date has not been announced yet. There is still time to buy additional HQNT and qualify for additional dividend. Conversely, anyone who sells their HQNT shares now will not receive this dividend.

H-Quotient Updates Significant Events
Wednesday November 30, 3:18 pm ET

VIENNA, VA--(MARKET WIRE)--Nov 30, 2005 -- H-Quotient, Inc. (Other OTC:HQNT.PK - News) -- On October 25, the Company announced completion of negotiations to sell its medical manufacturing subsidiary, Stewart & Shaw Inc., to Standard Holdings Group Ltd. (Other OTC:SNDH.PK - News). That transaction is now being finalized and from the consideration received, the Company expects to distribute one share of SNDH for every two shares of HQNT stock. The finalization of this dividend will be announced along with the record date. The shares will be restricted for two years or until a registration is filed. This transaction is expected to take place during December 2005.
HQNT management changes are being contemplated as the Company seeks to expand its core medical software business and complete its prior years' audited financial statements.

This announcement may contain, in addition to historical information, certain forward-looking statements that involve risks and uncertainties. There is no assurance that this transaction will be completed. Such statements reflect management's current views and are based on certain assumptions. Actual results could differ materially from the assumptions currently anticipated.

For more information visit the H-Quotient web site at www.hquotient.com.



Contact:
Contact:
H-Quotient, Inc.
(703) 821-3434



------------------------------------------------
Source: H-Quotient, Inc.

Fortune 500 Multi-National Purchases Bulldog Technologies' MiniBOSS(TM) Supply Chain Security Management Solution

RICHMOND, British Columbia, Nov 30, 2005 (BUSINESS WIRE) -- Bulldog Technologies Inc. ( BLLD ), premier provider of wireless security solutions and sensor networks that monitor, track and secure assets in the supply chain, announced today that yet another undisclosed "Fortune 500" company specializing in grocery food products has issued their first purchase order for the Bulldog MiniBOSS(TM) covert tracking and loss-prevention solution. Bulldog honors the customer's request for anonymity to preserve the integrity of their DLR (Deter-Locate-Recover) operations.

After careful consideration and due diligence, this international multi billion dollar company has selected Bulldog's MiniBOSS(TM) units to protect their goods in transit. After this initial stage, the company intends to implement the system throughout their supply chain, securing delivery of their food products.

The MiniBOSS(TM) System provides an advanced facility to secure, track and recover product shipments and also advances the company's cost savings model while providing the possibility of reduced rates for insurance coverage. As such, this Bulldog customer has expressed interest in taking full advantage of all direct and indirect benefits associated with the deployment of the MiniBOSS(TM) system.

The Bulldog MiniBOSS(TM) is a cellular-based true-AGPS covert asset recovery device. It is designed to work in conjunction with Bulldog's web-based software, allowing users to securely track their shipments using a standard PC. Since the MiniBOSS(TM) operates on an AGPS platform, its signal sensitivity is many times that of previous technologies. Additionally, the MiniBOSS(TM) can rely on both cellular tower triangulation and GPS satellite location to pinpoint the location of transportable materials throughout the United States.

John Cockburn, President and CEO of Bulldog Technologies, said today, "To be able to assist this Fortune 500 organization in protecting its supply chain with the Bulldog MiniBOSS(TM) is a great honor. They are a storied company with a long history and are a pillar in their community and in the business community in general. Our expectation is that this positive beginning is a prelude to a long and mutually beneficial business relationship."

About Bulldog Technologies

Bulldog Technologies Inc. develops and manufactures real-time wireless security solutions and sensor networks. The Company serves an international clientele consisting of Governments, Law Enforcement, Large Enterprise and the Transportation and Storage Sectors, to name a few.

Bulldog's solutions allow dispatchers, security personnel, law enforcement and loss-prevention professionals, emergency response teams and cargo transport drivers to monitor, track and secure valuable cargo during the transport, storage and delivery supply-chain process.

For further information, visit Bulldog on the Web at http://www.bulldog-tech.com

SAFE HARBOR STATEMENT: This news release contains "forward-looking statements" that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "future," "plan" or "planned," "will" or "should," "expected," "anticipates," "draft," "eventually" or "projected." You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements, including the risks that our products may not achieve customer acceptance or that they will not perform as expected, that customer trials will not lead to future sales, and other risks identified in our annual report on Form 10-K and other filings with the SEC. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements are made as of the date hereof and Bulldog Technologies Inc. undertakes no obligation to update such statements.

SOURCE: Bulldog Technologies Inc.

Bulldog Technologies Inc.
Jan Roscovich, 604-271-8656 (Press Contact)
jroscovich@bulldog-tech.com


Copyright Business Wire 2005

FONAR RSNA2005 Message to Attendees: Upright MRI Imaging Improves Patient Outcome

MELVILLE, N.Y.--(BUSINESS WIRE)----FONAR Corporation (NASDAQ:FONR), The Inventor of MR Scanning(TM), reported today results from its exhibition at the 2005 Annual Meeting of the Radiological Society of North America (RSNA) in Chicago.

Francis W. Smith, M.D. of the University of Aberdeen in Scotland and pioneer in the field of magnetic resonance imaging is one of the keynote speakers at the FONAR exhibit. Dr. Smith said, "We have scanned thousands of patients in a multitude of positions and have completed several clinical studies using our FONAR Upright(TM) MRI We routinely scan spines in five positions, - normal, upright, in flexion, in extension, rotation, and laterally - none of which can be duplicated on any other MRI scanner, Our diagnoses are based upon the full complement of information derived from all the important spinal postures, and we subsequently monitor every patient's treatment and progress. I can say unequivocally that Position(TM) imaging improves patient outcome."

Dr. Raymond Damadian, president and founder of FONAR, said, "At this year's RSNA, we are challenging the radiological community with this question: 'Are you missing pathology daily?' Our entire presentation is geared to answer that question with a resounding 'Yes, you are, and the only solution to the problem is the Upright(TM) MRI.' We're displaying many compelling cases where the Upright(TM) has beneficially changed the outcome for the patient, the ultimate object of every medical technology. We are proud of that. At this year's RSNA our team of distinguished professors is presenting lectures demonstrating numerous examples where Upright(TM) weight-bearing imaging has dramatically altered the results being achieved with patients."

This year FONAR is enjoying a premiere location on the floor of RSNA. The Company's 80' x 80' exhibit is among the largest at the show. With some 60,000 in attendance, the RSNA meeting is the largest medical meeting in the world. The mission of the Radiological Society of North America is to promote and develop the highest standards of radiology and related sciences through education and research.

About the Positional MRI Research Centre

The Positional MRI Research Centre operates at Woodend Hospital, University of Aberdeen, Scotland, United Kingdom. The University of Aberdeen has been designated by the European Union (EU) as one of Europe's centers of excellence in medical imaging. This year, the University of Aberdeen celebrated the 25th anniversary of the introduction of the first MRI into regular clinical use at the Aberdeen Royal Infirmary, then headed by Dr. Francis Smith.

About FONAR

FONAR was incorporated in 1978, making it the first, oldest and most experienced manufacturer of Magnetic Resonance (MR) imaging scanners in the industry. FONAR introduced the world's first commercial MR in 1980, and went public in 1981. Since its inception FONAR has installed over 300 MR scanners worldwide. Its stellar product line features the Upright(TM) MRI (also known as the Stand-Up(TM) MR), the only whole-body MR that performs Position(TM) Imaging (pMRI(TM)) and scans patients in numerous weight-bearing positions, i.e. standing, sitting, in flexion and extension, as well as the conventional lie-down position. The FONAR Upright(TM) MRI often sees the patient's problem that other scanners cannot because they are lie-down-only scanners. With over 100,000 patients scanned, the patient-friendly Upright(TM) MRI has a near-zero claustrophobic rejection rate by patients. As one Upright(TM) MRI customers puts it, "If the patient is claustrophobic in our Upright(TM) MRI, he'd be claustrophobic in our parking lot," Another user states in his advertising, "Upright MRI - No More Claustrophobia - The Tube is Gone." Approximately 85% of patients are scanned sitting while watching a 42" flat screen TV. FONAR's latest MRI scanner is the FONAR 360(TM), a room-size recumbent scanner that optimizes openness while facilitating physician access to the patient. FONAR is headquartered on Long Island, New York, and has approximately 500 employees.

The Inventor of MR Scanning, True Flow, Stand-Up, Upright, Position, PMRI and The Proof is in the Picture are trademarks of FONAR.

Be sure to visit FONAR's Web site for Company product and investor information: www.fonar.com

This release may include forward-looking statements from the company that may or may not materialize. Additional information on factors that could potentially affect the company's financial results may be found in the company filings with the Securities and Exchange Commission.

FONAR Corporation Daniel Culver, 631-694-2929 Fax: 631-390-1709 invest@fonar.com http://www.fonar.com or Darrow Associates, Inc. Jordan M. Darrow, 631-367-1866 Fax: 631-614-3612 jdarrow@optonline.net

11/30/2005 07:18 ET

Show me the money. All you have to do is read...
--------------------------------------------------------
instaCare Corp., (OTCBB:INCA - News) a leading Wi-Fi PDA technology provider to the lodging and satellite media industries, the developer of patent-pending technologies for e-health and EMR applications and the distributor of life-saving prescription drugs, today reported financial results for the three and nine months ended Sept. 30, 2005. Highlights of the quarter and recent weeks include:

Revenues grow substantially in third quarter as prescription diagnostic sales ramp up

Operating loss narrows as overhead costs decline

Pharmacy licenses granted in New Jersey, Arizona and North Dakota

instaCare announced that revenues for the third quarter ending September 30, 2005 were $1,007,216, up significantly from $51,670 in the same quarter a year ago. The increase in revenues was due to sales of pharmaceutical supplies and revenues from instaCare ResidenceWare lodging networks as the Company began operations during 2005.

LLLI's new website is up and running as of today.
Looks very impressive.

CLICK HERE:
http://lamperdlesslethal.com

Anyone who does their homework here knows that INCA is being manipulated down right now by artificial forces. This stock was at .019 yesterday and on the rise based on the strong revenue growth and other progress just reported. Do not give into the manipulators playing with this stock in the short term. Sooner or later INCA will rise to the higher valuations it deserves. Maybe even starting tomorrow.

Healthnostics Announces Search Results Clustering for MedBioWorld.com Portal

BETHESDA. MD, Nov 29, 2005 (MARKET WIRE via COMTEX) -- Healthnostics, Inc. (OTC: HNST), a clinical information system, and medical and bioscience informatics company, today announced the availability of search results clustering software for Health News Explorer, an exclusive search engine that mines nearly 30,000 Reuters Health News articles on the Healthnostics portal, http://www.MedBioWorld.com. Health News Explorer uses keyword search, find-similar context search, term-suggest technology, and now clustering to semantically search the Reuters Health news collection.

Clustering brings a sense of order to search results, which are traditionally arranged by their ordinal ranking without much consideration for navigation. Health News Explorer algorithmic clustering places Reuters news documents having similar frequently occurring words or phrases into groups by topic "on-the fly" for easy navigation and discovery.

"The world of search now demands fast, relevant and user-friendly results," said Alan Grofe, president. "MedBioWorld professional users now can explore our extensive Reuters Health news collection and view results in a topical hierarchy, making it easier to find and pinpoint relevant health and industry information.''

The Reuters Health News database contains professional news articles covering the clinical, business and political issues in health and medicine. The Reuters Health content incorporates breaking medical news such as core scientific research developments and summaries of news from original peer-reviewed journals (including New England Journal of Medicine, Journal of the American Medical Association (JAMA), Lancet and British Medical Journal (BMJ) and annual scientific meetings and symposia.

About Healthnostics

Healthnostics, Inc. is a clinical information system, and medical and bioscience informatics company. Healthnostics provides comprehensive patient clinical monitoring and risk reduction systems to acute care hospitals and utilizes its' Internet portals to deliver healthcare and bioscience information to its hospital clients, industry professionals and the general public. Healthnostics products include MedGuardian (http://www.healthnostics.com/pages/2/index.htm), a patient care monitoring and risk management system for hospitals that's fully Web-based; MedBioWorld(TM) (http://www.medbioworld.com/), the largest professional medical and bioscience directory resource and reference portal site on the Internet; and, FamilyMedicalNet (http://www.familymedicalnet.com/), a companion consumer healthcare information portal.

For further information please visit Healthnostics www.healthnostics.com, MedGuardian www.med-guardian.com, MedBioWorld www.medbioworld.com, and FamilyMedicalNet www.familymedicalnet.com. For more information on Reuters health news services visit http://www.reutershealth.com.

This announcement may contain, in addition to historical information, certain forward-looking statements that involve risks and uncertainties. Such statements reflect management's current views and are based on certain assumptions. Actual results could differ materially from the assumptions currently anticipated.


Contacts:

Jason Pollack
561-731-2215

Stuart T. Smith
P. 512-267-2430
F. 512-267-2530
SSmith@SmallCapVoice.com www.SmallCapVoice.com

SOURCE: Healthnostics, Inc.



CONTACT: mailto:SSmith@SmallCapVoice.com
http://www.SmallCapVoice.com


Copyright 2005 Market Wire, All rights reserved.

-0-

SUBJECT CODE: Computers and Software:Networking
Medical and Healthcare:Facilities and Providers
Medical and Healthcare:Healthcare

CORRECTING and REPLACING instaCare Corp. Reports Substantial Increase in Revenues in Third Quarter
Monday November 28, 4:06 pm ET

NEW YORK--(BUSINESS WIRE)--Nov. 28, 2005--In the financial table titled "Consolidated Balance Sheet," under the entry for common stock - shares authorized, the correct amount should read: 1,200,000,000 shares authorized (sted 200,000,000).
The corrected release reads:

INSTACARE CORP. REPORTS SUBSTANTIAL INCREASE IN REVENUES IN THIRD QUARTER

instaCare Corp., (OTCBB:INCA - News) a leading Wi-Fi PDA technology provider to the lodging and satellite media industries, the developer of patent-pending technologies for e-health and EMR applications and the distributor of life-saving prescription drugs, today reported financial results for the three and nine months ended Sept. 30, 2005. Highlights of the quarter and recent weeks include:

Revenues grow substantially in third quarter as prescription diagnostic sales ramp up
Operating loss narrows as overhead costs decline
Pharmacy licenses granted in New Jersey, Arizona and North Dakota
instaCare announced that revenues for the third quarter ending September 30, 2005 were $1,007,216, up significantly from $51,670 in the same quarter a year ago. The increase in revenues was due to sales of pharmaceutical supplies and revenues from instaCare ResidenceWare lodging networks as the Company began operations during 2005.

Total expenses for the third quarter of 2005 were $514,139, down 35% from $795,407 for the third quarter of 2004. Lower expenses were primarily due to lower overhead costs and a reduced need for outside service providers and consultants. The Company reported an operating loss of $(460,313), and a net loss of $(873,168), or $(0.0) per basic and diluted share for the third quarter ending September 30, 2005, compared with an operating loss of $(743,737), and a net loss of $(763,537) for the prior year quarter, or $(0.00) per basic and diluted share.

Robert Cox, chief executive officer of instaCare, stated, "We are pleased to see such a strong demand for prescription diagnostics, one of our key products. The fact that we have entered the marketplace only recently and have already generated over $4 million in sales this year validates both our business strategy and our execution. In addition, we have obtained several wholesale and retail pharmacy licenses in geographically dispersed states, which will allow us to build a balanced national distribution network that can serve all regions of the United States economically and efficiently. We now have licenses in New Jersey, Arizona and North Dakota."

Revenues for the nine months ended September 30, 2005 were $4,177,454, compared with revenues of $181,108 for the nine months ended September 30, 2004. The increase was primarily attributed to the Company's commencement of activities in 2005 and subsequent sales activities. Total expenses for the first nine months of 2005 were $2,396,656, down 17% from total expenses of $2,896,518 for the first nine months of 2004. instaCare reported a net loss of $(3,176,098), or $(0.01) per basic and diluted share, for the first three quarters of 2005, compared with a net loss of $3,572,898, or $(0.02) per basic and diluted share for the first three quarters of 2004.

instaCare had cash and equivalents of $1,219,836 as of September 30, 2005.

Forward Looking Statements:

This release contains forward-looking statements about our business or financial condition that reflect our assumptions and beliefs based on information currently available. We can give no assurance that the expectations indicated by such forward-looking statements will be realized. There may be other risks and circumstances that we are unable to predict. When used in this release, words such as "believes," "expects," "forecasts," "intends," "projects," "plans," "anticipates," "estimates" and similar expressions are intended to identify forward-looking statements, although there may be certain statements not accompanied by such expressions.

For further information, visit the company's Web Site: http://www.instacare.net or http://www.caredecision.net

InstaCare Corp.
Consolidated Statement of Operations
Unaudited

(unaudited) (unaudited)
For the three For the nine
months ended months ended
September 30, September 30,
----------------------------------------------------
2005 2004 2005 2004
----------------------------------------------------

Revenue $ 1,007,216 $ 51,670 $ 4,177,454 $ 181,108
Cost of sales 953,391 - 3,717,284 -
----------------------------------------------------

Gross profit 53,826 51,670 460,170 181,108
----------------------------------------------------

Expenses:
Hardware costs 5,779 95,638 48,743 185,431
General &
administrative
expenses 104,214 44,020 346,829 185,338
Consulting 16,400 - 26,800 -
Payroll expense 149,066 100,066 624,633 265,011
Officers
salaries 71,250 - 123,750 -
Professional
fees 90,135 36,459 448,662 330,314
Stock-based
compensation
for employee
benefits - 33,600 115,290 33,600
Stock-based
compensation
for
professional
fees - - 159,750 -
Stock-based
compensation
for consulting
services 64,159 410,850 462,789 1,399,369
Software
development - 54,932 - 141,240
Impairment loss
on operating
assets - - - 278,428
Depreciation 13,136 19,842 39,410 77,787
----------------------------------------------------
Total
expenses 514,139 795,407 2,396,656 2,896,518
----------------------------------------------------

Net operating
(loss) (460,313) (743,737) (1,936,486) (2,715,410)

Other income
(expense):
Loss on debt
settlement (107,500) - (196,153) (377,136)
Loss - related
party (85,430) - (221,680) -
Interest income 4,845 1,200 13,861 2,204
Merger expenses - - (79,500) -
Merger expenses
- non cash - - (8,450) -
Financing costs - - - (408,255)
Financing costs
- non cash (39,500) - (353,500) -
Interest
expense (185,270) (21,000) (319,470) (74,301)
Interest
expense - non
cash - - (74,720) -
----------------------------------------------------

Net (loss) $ (873,168)$ (763,537) (3,176,098) (3,572,898)
====================================================

Weighted average
number of common
shares
outstanding -
basic and fully
diluted 492,298,111 216,394,551 413,941,152 183,469,542
====================================================

Net (loss) per
share -
basic and fully
diluted $ (0.00)$ (0.00) (0.01) (0.02)
====================================================


InstaCare Corp.
Consolidated Balance Sheet
Unaudited

(unaudited)
September 30,
2005
Assets

Current assets:
Cash and equivalents $ 1,219,836
Accounts receivable 228,540
Inventory 30,884
Notes receivable 106,944
---------------
Total current assets 1,586,204
---------------

Fixed assets, net 144,140

Other assets:
Amortizable loan fees, net 32,917
---------------
Total other assets 32,917
---------------

1,763,261
===============

Liabilities and Stockholders' Equity

Current liabilities:
Accrued liabilities 215,214
Convertible note payable 1,060,796
Revolving line of credit 152,309
---------------
Total current liabilities 1,428,319
---------------

Stockholders' equity:
Preferred stock, $0.001 par value, 5,000,000 shares
authorized, 207,526 shares issued and outstanding 208
Preferred series "C" stock, $0.001 par value, 20,000
shares authorized, 20,000 shares issued and
outstanding 20
Common stock, $0.001 par value, 1,200,000,000 shares
authorized, 488,777,249 shares issued and outstanding 506,547
Additional paid-in capital 13,243,827
Prepaid share-based compensation (116,002)
Current year accumulated (deficit) (3,176,098)
Accumulated (deficit) (10,123,560)
---------------
334,942
---------------
$ 1,763,261
===============



Contact:
instaCare Corp.
Keith Berman, 805-446-1973
kmb@instacare.net
or
Investor Relations:
Lippert/Heilshorn & Associates, Inc.
Kim Sutton Golodetz / Lisa Lindberg, 212-838-3777
kgolodetz@lhai.com / llindberg@lhai.com

--------------------------------------------------------------------------------
Source: instaCare Corp.

Law Enforcement Associates Receives Supplemental Order for Wireless Video Kits from U.S. Government Agency

$657,000 Add-on Order Pushes Total Value of Contract to $1,759,000

YOUNGSVILLE, N.C., Nov 28, 2005 /PRNewswire-FirstCall via COMTEX/ -- Law Enforcement Associates Corporation (LEA) ( AID ), a leading provider of surveillance and security products to the global law enforcement, military, security and corrections markets, today announced it has received an add-on order for its Wireless Video Kits from an agency of the U.S. Government. The $657,000 requisition is the second supplemental order LEA has received under a contract that was originated in May. Total value of the contract is now $1,759,000, of which $1,102,000 has been shipped.

Paul Feldman, president of LEA, said, "While we are not permitted to provide additional detail regarding this contract or the products involved, the order is a clear indication of the growing demand for our suite of leading-edge surveillance equipment from a broad range of government and law enforcement agencies."

Feldman said the majority of the revenue from the latest order will be recorded during the first quarter of 2006. "This represents a solid start to the coming fiscal year. We expect that our expanded sales and marketing efforts will allow us to build on this early momentum."

About Law Enforcement Associates, Inc.

LEA is a leading security and surveillance technology company that manufactures and markets a diverse product line to the worldwide law enforcement, military, security and corrections markets. The company's Audio Intelligence Devices (AID) division has been serving the law enforcement sector for more than 30 years and is one of the most respected names in the surveillance equipment industry. LEA's products are used by a wide variety of government and non-governmental agencies, as well as public and private companies. These include military bases, nuclear facilities, embassies, government installations, oil refineries, United Nations and NATO locations. LEA's products also have been used at high-profile events such as the Summer & Winter Olympics, Super Bowl, U.S. Golf Championship, and the Democratic and Republican National Conventions. Its products include the Under Vehicle Inspection System (UVIS), EDK123 (Explosive Detection Kit), Bloodhound GPS Tracking System, Letter-bomb Visualizer Spray, and a wide variety of Audio & Video Surveillance Equipment. Headquartered in Youngsville, N.C., the company has been featured in many industry publications and websites. For more information, please visit www.leacorp.com.

Forward-Looking Information

The statements in this news release contain forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve certain risks, assumptions and uncertainties, including the inability to generate and secure the necessary product sales, or the lack of acceptance of the company's products by its customers. In each case actual results may differ materially from such forward-looking statements. The company does not undertake to publicly update or revise its forward-looking statements even if experience or future changes make it clear that any projected results (expressed or modified) will not be realized.

SOURCE Law Enforcement Associates Corporation

Geoff High of Pfeiffer High Investor Relations, Inc., +1-303-393-7044 for Law
Enforcement Associates Corporation

http://www.prnewswire.com


Copyright (C) 2005 PR Newswire. All rights reserved.

instaCare Corp. Reports Substantial Increase in Revenues in Third Quarter

NEW YORK, Nov 28, 2005 (BUSINESS WIRE) -- instaCare Corp., ( INCA ) a leading Wi-Fi PDA technology provider to the lodging and satellite media industries, the developer of patent-pending technologies for e-health and EMR applications and the distributor of life-saving prescription drugs, today reported financial results for the three and nine months ended Sept. 30, 2005. Highlights of the quarter and recent weeks include:

-- Revenues grow substantially in third quarter as prescription diagnostic sales ramp up

-- Operating loss narrows as overhead costs decline

-- Pharmacy licenses granted in New Jersey, Arizona and North Dakota

instaCare announced that revenues for the third quarter ending September 30, 2005 were $1,007,216, up significantly from $51,670 in the same quarter a year ago. The increase in revenues was due to sales of pharmaceutical supplies and revenues from instaCare ResidenceWare lodging networks as the Company began operations during 2005.

Total expenses for the third quarter of 2005 were $514,139, down 35% from $795,407 for the third quarter of 2004. Lower expenses were primarily due to lower overhead costs and a reduced need for outside service providers and consultants. The Company reported an operating loss of $(460,313), and a net loss of $(873,168), or $(0.0) per basic and diluted share for the third quarter ending September 30, 2005, compared with an operating loss of $(743,737), and a net loss of $(763,537) for the prior year quarter, or $(0.00) per basic and diluted share.

Robert Cox, chief executive officer of instaCare, stated, "We are pleased to see such a strong demand for prescription diagnostics, one of our key products. The fact that we have entered the marketplace only recently and have already generated over $4 million in sales this year validates both our business strategy and our execution. In addition, we have obtained several wholesale and retail pharmacy licenses in geographically dispersed states, which will allow us to build a balanced national distribution network that can serve all regions of the United States economically and efficiently. We now have licenses in New Jersey, Arizona and North Dakota."

Revenues for the nine months ended September 30, 2005 were $4,177,454, compared with revenues of $181,108 for the nine months ended September 30, 2004. The increase was primarily attributed to the Company's commencement of activities in 2005 and subsequent sales activities. Total expenses for the first nine months of 2005 were $2,396,656, down 17% from total expenses of $2,896,518 for the first nine months of 2004. instaCare reported a net loss of $(3,176,098), or $(0.01) per basic and diluted share, for the first three quarters of 2005, compared with a net loss of $3,572,898, or $(0.02) per basic and diluted share for the first three quarters of 2004.

instaCare had cash and equivalents of $1,219,836 as of September 30, 2005.

Forward Looking Statements:

This release contains forward-looking statements about our business or financial condition that reflect our assumptions and beliefs based on information currently available. We can give no assurance that the expectations indicated by such forward-looking statements will be realized. There may be other risks and circumstances that we are unable to predict. When used in this release, words such as "believes," "expects," "forecasts," "intends," "projects," "plans," "anticipates," "estimates" and similar expressions are intended to identify forward-looking statements, although there may be certain statements not accompanied by such expressions.

For further information, visit the company's Web Site: http://www.instacare.net or http://www.caredecision.net

InstaCare Corp.
Consolidated Statement of Operations
Unaudited

(unaudited) (unaudited)
For the three For the nine
months ended months ended
September 30, September 30,
----------------------------------------------------
2005 2004 2005 2004
----------------------------------------------------

Revenue $ 1,007,216 $ 51,670 $ 4,177,454 $ 181,108
Cost of sales 953,391 - 3,717,284 -
----------------------------------------------------

Gross profit 53,826 51,670 460,170 181,108
----------------------------------------------------

Expenses:
Hardware costs 5,779 95,638 48,743 185,431
General &
administrative
expenses 104,214 44,020 346,829 185,338
Consulting 16,400 - 26,800 -
Payroll expense 149,066 100,066 624,633 265,011
Officers
salaries 71,250 - 123,750 -
Professional
fees 90,135 36,459 448,662 330,314
Stock-based
compensation
for employee
benefits - 33,600 115,290 33,600
Stock-based
compensation
for
professional
fees - - 159,750 -
Stock-based
compensation
for consulting
services 64,159 410,850 462,789 1,399,369
Software
development - 54,932 - 141,240
Impairment loss
on operating
assets - - - 278,428
Depreciation 13,136 19,842 39,410 77,787
----------------------------------------------------
Total
expenses 514,139 795,407 2,396,656 2,896,518
----------------------------------------------------

Net operating
(loss) (460,313) (743,737) (1,936,486) (2,715,410)

Other income
(expense):
Loss on debt
settlement (107,500) - (196,153) (377,136)
Loss - related
party (85,430) - (221,680) -
Interest income 4,845 1,200 13,861 2,204
Merger expenses - - (79,500) -
Merger expenses
- non cash - - (8,450) -
Financing costs - - - (408,255)
Financing costs
- non cash (39,500) - (353,500) -
Interest
expense (185,270) (21,000) (319,470) (74,301)
Interest
expense - non
cash - - (74,720) -
----------------------------------------------------

Net (loss) $ (873,168)$ (763,537) (3,176,098) (3,572,898)
====================================================

Weighted average
number of common
shares
outstanding -
basic and fully
diluted 492,298,111 216,394,551 413,941,152 183,469,542
====================================================

Net (loss) per
share -
basic and fully
diluted $ (0.00)$ (0.00) (0.01) (0.02)
====================================================


InstaCare Corp.
Consolidated Balance Sheet
Unaudited

(unaudited)
September 30,
2005
Assets

Current assets:
Cash and equivalents $ 1,219,836
Accounts receivable 228,540
Inventory 30,884
Notes receivable 106,944
---------------
Total current assets 1,586,204
---------------

Fixed assets, net 144,140

Other assets:
Amortizable loan fees, net 32,917
---------------
Total other assets 32,917
---------------

1,763,261
===============

Liabilities and Stockholders' Equity

Current liabilities:
Accrued liabilities 215,214
Convertible note payable 1,060,796
Revolving line of credit 152,309
---------------
Total current liabilities 1,428,319
---------------

Stockholders' equity:
Preferred stock, $0.001 par value, 5,000,000 shares
authorized, 207,526 shares issued and outstanding 208
Preferred series "C" stock, $0.001 par value, 20,000
shares authorized, 20,000 shares issued and
outstanding 20
Common stock, $0.001 par value, 200,000,000 shares
authorized, 488,777,249 shares issued and outstanding 506,547
Additional paid-in capital 13,243,827
Prepaid share-based compensation (116,002)
Current year accumulated (deficit) (3,176,098)
Accumulated (deficit) (10,123,560)
---------------
334,942
---------------
$ 1,763,261
===============


SOURCE: instaCare Corp.

instaCare Corp.
Keith Berman, 805-446-1973
kmb@instacare.net
or
Investor Relations:
Lippert/Heilshorn & Associates, Inc.
Kim Sutton Golodetz / Lisa Lindberg, 212-838-3777
kgolodetz@lhai.com / llindberg@lhai.com


Copyright Business Wire 2005

Radiologist Buys and Installs The Fifth FONAR Upright MRI In New Jersey and Says To His Patients: ''Upright MRI - No More Claustrophobia - The Tunnel Is Gone''

MELVILLE, N.Y.--(BUSINESS WIRE)----FONAR Corporation (NASDAQ-FONR), The Inventor of MR Scanning(TM), announced today that it has installed an Upright(TM) MRI in Cherry Hill, New Jersey bringing the total to five installed in New Jersey.

G. Tom Morea, M.D., one of the world's most experienced, fellowship trained MRI radiologists with board certification, said today, "During my twenty-two years as a Radiologist engaged in reading MR images, I have worked on scanners of nearly every MRI manufacturer in the industry. This includes several Siemens, GE, Marconi, Picker, Philips, Shimatsu and even Diasonics MRI's. I have also worked on both low-field Open and high-field Open Hitachi scanners. Now that I have free reign to pick the system that will be best for my patients, I choose FONAR."

Dr. Morea continued, "Although we have only been in operations a few weeks, already our patients and their referring physicians are delighted. It is obvious why our patients are happy, as they are no longer anxious while being scanned in the vertical configuration of this magnet. We have already provided excellent scans on patients who could not be studied on other 'open' MRI's. They were thrilled! That is why we say, Upright MRI - No More Claustrophobia - The Tunnel Is Gone!"

"Our referring physicians have been impressed with the image quality, and commented that the studies are quite comparable to that of a 1.5 Tesla," said Dr. Morea. "In the case of spine studies, we are able to image the fully weight-loaded spine, the only way to optimally assess spine pathology. In the two short weeks we have been scanning, I have already diagnosed disc herniations that were only apparent with flexion or extension and not apparent on neutral views. Evaluating the spine with its weight load removed, as in the case of the recumbent only tunnel MRI, represents an incomplete evaluation of the patient's spine problem."

"I am looking forward to the visualization of shoulder pathology in various views that are possible on the Upright(TM) MR that are not easily obtained on other systems, and to explore weight-bearing studies of the knees and ankles," added Dr. Morea. "Our technologists are also happy with FONAR's Upright(TM) MRI. It is simple to operate and FONAR's application teams are readily accessible for guidance as needed."

Dr. Morea concluded, "I have not been this excited about a new MRI technology for a very long time, and can't wait to put this scanner through its paces."

Upright MRI of Cherry Hill is located at 701 Route 38 East in Cherry Hill, New Jersey. The telephone number is (856) 486-9000.

This week from November 27th - December 1st , FONAR is exhibiting at the Technical Exhibit of the 91st Scientific Assembly & Annual Meeting of the Radiological Society of North America (RSNA) in Chicago. Over 60,000 radiologists, physicians and allied health care professionals from around the world are expected to attend the conference. The FONAR exhibit is among the largest displays at this years RSNA.

About FONAR

FONAR was incorporated in 1978, making it the first, oldest and most experienced MRI manufacturer in the industry. FONAR introduced the world's first commercial MRI in 1980, and went public in 1981. Since its inception FONAR has installed over 300 MRI scanners worldwide. Their stellar product line includes the Upright(TM) MRI (also known as the Stand-Up(TM) MRI), the only whole-body MRI that performs Position(TM) imaging (pMRI(TM)) and scans patients in numerous weight-bearing positions, i.e. standing, sitting, in flexion and extension, as well as the conventional lie-down position. The FONAR Upright(TM) MRI often sees the patient's problem that other scanners cannot because they are lie-down only. With over 100,000 patients scanned, the patient-friendly Upright(TM) MRI has a near zero claustrophobic rejection rate by patients. As a FONAR customer states, "If the patient is claustrophobic in this scanner, they'll be claustrophobic in my parking lot." Approximately 85% of patients are scanned sitting while they watch a 42" flat screen TV. FONAR's latest MRI scanner is the FONAR 360(TM), a room-size recumbent scanner that optimizes openness while facilitating physician access to the patient. FONAR is headquartered on Long Island, New York, and has approximately 500 employees.

The Inventor of MR Scanning True Flow, Stand-Up, Upright, Position, PMRI and The Proof is in the Picture are trademarks of FONAR.

Be sure to visit FONAR's Web site for Company product and investor information: www.fonar.com

This release may include forward-looking statements from the company that may or may not materialize. Additional information on factors that could potentially affect the company's financial results may be found in the company filings with the Securities and Exchange Commission.

FONAR Corporation Daniel Culver, 631-694-2929 Fax: 631-390-1709 http://www.FONAR.com invest@FONAR.com or Darrow Associates, Inc. Jordan M. Darrow, 631-367-1866 Fax: 631-614-3612 jdarrow@optonline.net

11/28/2005 07:00 ET

Any time you see a poster making constant negative remarks and trying to downplay all the positive points you can be sure they have a hidden agenda. INCA has been climbing very well this week and that does not sit well with some people. These people may be former shareholders who sold for a loss and just post out of spite (the dumbest use of anyone's time) or they may think they can knock the stock down to where they can buy in cheaper (dishonest and counter-productive since their own posts will work against them after they buy) or they may be true enemies (competitors or short sellers) trying to cause harm any way they can. In any event, any poster that is constantly negative should not be taken seriously.

IDSI Concludes Collaborative Agreement with Schering AG

FORT LAUDERDALE, Fla., Nov 25, 2005 /PRNewswire-FirstCall via COMTEX/ -- Imaging Diagnostic Systems, Inc., ( IMDS ) announced today that Schering AG has completed the evaluation of their new fluorescence dyes with three modified CT Laser Mammography systems. The loaned systems had been modified to Schering AG's specifications and will be returned to IDSI.

IDSI believes that fluorescence dyes and other vasoactive agents may help improve the cancer detection accuracy of Laser Breast imaging. The company will continue research in this area.

The CT Laser Mammography (CTLM(R)) system is the first patented breast imaging system that utilizes state-of-the-art laser technology and patented algorithms to create 3-D cross-sectional images of the breast. It is a non-invasive, painless examination that does not expose the patient to radiation or require breast compression. Imaging Diagnostic Systems has received CE Marking, CMDCAS (Canada), Canadian License, China SFDA approval, UL listing, ISO 9001:2000-13488 certification and FDA export certification for its CT Laser Breast Imaging system. The Company is seeking PreMarket Approval (PMA) from the Food and Drug Administration (FDA) for its CTLM(R) system to be used as an adjunct to mammography.

Please visit Imaging Diagnostic Systems' website at: http://www.imds.com for additional information.

In conjunction with the provisions of the Safe Harbor section of the Private Securities Litigation Reform Act of 1995, this news release may contain forward-looking statements pertaining to future anticipated projected plans, performances and developments, as well as other statements relating to future operations. All such forward-looking statements are necessarily only estimates of future results and there can be no assurance that actual results will not materially differ from expectation. Further information on potential factors that could affect Imaging Diagnostic Systems, Inc. is included in the Company's filing with the Securities and Exchange Commission.

Investor Relations: Rick Lutz

404-261-1196
lcgroup@mindspring.com


SOURCE Imaging Diagnostic Systems, Inc.

Investor Relations: Rick Lutz for Imaging Diagnostic Systems, Inc., +1-404-261-1196,
lcgroup@mindspring.com

http://www.prnewswire.com


Copyright (C) 2005 PR Newswire. All rights reserved.

Global ePoint Wins First Airport Order for Digital Surveillance System; Installation Expected to Support Other Airport Sales

CITY OF INDUSTRY, Calif., Nov 23, 2005 (BUSINESS WIRE) -- Global ePoint, Inc. ( GEPT ), a leading manufacturer of security technologies for the aviation, law enforcement, and commercial / industrial markets, today announced that its digital surveillance system has been chosen by the Laughlin/Bullhead City International Airport, which serves a tri-state area centered on southern Nevada. The order will be Global ePoint's first-ever airport installation.

Commenting on the order, Global ePoint CEO Toresa Lou said, "This order carries significance for Global ePoint far beyond its size. Since we plan an aggressive program to pursue opportunities at airports around the world, it will be very helpful to have a working installation that will showcase the advantages of our system, and as such, this installation opens the door to a very large market worldwide." According to the US Department of Transportation, there are more than 5,000 airports in the US that are used by public passengers, and many times that number worldwide. "This is clearly a multi-billion dollar market," said Ms. Lou, "where our products are very well suited and where we have a good opportunity to take a major portion of this market."

"In partnership with John Paskell, Executive Director of the Mojave County Airport Authority, we reviewed the systems that were applicable to airport applications, and concluded that Global ePoint's technology has a number of remarkable features and offers the best performance and value," said Chris Chatwin of University Lock Company, a systems integration firm. "In restricted areas, for example, we can set the system to notify us when any movement takes place and to automatically record that event. Further, the notification can go beyond the video monitoring screens to notify wireless devices that security personnel may carry, such as cell phones, two-way radios, pagers, and hand-held email units. Also, when reviewing recordings, we can zero in on portions of the image area, create a list of the exact times that movement took place, and replay any or all of those events."

Beyond airport surveillance, Global ePoint is also targeting other applications of its digital video technology. "Our surveillance systems have been installed in passenger aircraft, police cars and first responder vehicles, police stations and prisons, banks, retail outlets, restaurants and other commercial applications," added Ms. Lou, "because the same advantages our technology brings to airports are also relevant in these settings".

About Global ePoint

Global ePoint designs, manufactures, sells and distributes digital video surveillance systems for the law enforcement, military, aviation and homeland security markets. On the cutting edge of digital technology, Global ePoint is developing new compression technologies and next-generation, secure network digital video systems and servers for a wide range of new markets, concentrating primarily on security and homeland defense applications. The Company also manufactures customized computing systems for industrial, business and consumer markets, as well as other specialized electronic products and systems. Complete vertical integration -- from design and manufacturing to sales and distribution -- allows the Company to capture efficiencies and maintain cost advantages in these growing markets, particularly homeland security. For more information, please visit http://www.globalepoint.com.

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to whether Global ePoint's technology will be used in other applications. Such statements are subject to certain risks and uncertainties, and actual circumstances, events or results may differ materially from those projected in such forward-looking statements. Factors that could cause or contribute to differences include, but are not limited to, whether other government agencies or businesses decide to use digital technology and if so, whether they will choose Global ePoint's systems. Other risks include delays in the introduction of new products; further approvals of regulatory authorities, and the Company's ability to obtain capital as and when needed. For a discussion of these and other factors that may cause actual events or results to differ from those projected, please refer to the Company's most recent annual report on Form 10-KSB and quarterly reports on Form 10-QSB, as well as other subsequent filings with the Securities and Exchange Commission. The Company cautions readers not to place undue reliance on any forward-looking statements. The Company does not undertake, and specifically disclaims any obligation, to update or revise such statements to reflect new circumstances or unanticipated events as they occur.

SOURCE: Global ePoint, Inc.

Global ePoint, Inc.
Paul Goodson, 909-839-1719
pgoodson@globalepoint.com
or
CEOcast, Inc.
Ed Lewis, 212-732-4300


Copyright Business Wire 2005

Bulldog Technologies is Proud to Announce Accomplished International Businessman, Bertrand Huchberger, Joins Board of Advisors to Assist Bulldog in Expansion through Europe

RICHMOND, British Columbia, Nov 23, 2005 (BUSINESS WIRE) -- Bulldog Technologies Inc. ( BLLD ), premier international provider of wireless security solutions and sensor networks that monitor, track and secure assets in the global supply chain, announces today that prominent business man, defense consultant and international aerospace and electronics pioneer, Bertrand Huchberger has joined Bulldog's Advisory Board.

Mr. Huchberger's presence as a permanent guiding force within Bulldog Technologies' management structure is expected to provide top-level access to key decision makers in North American and European political and business circles.

In addition to his extensive career in the US Air Force and subsequent private sector success, Huchberger holds an Engineering Degree from the US Naval Academy, an MS in Computer Science from the Georgia Institute of Technology and an MBA in Management & Marketing from Utah State. He is fluent in French and speaks the Italian, German, Swedish languages with proficiency.

Mr. Huchberger and his private international consulting group have provided business strategy and development services in the areas of Defense, International Telecom, IT and Aerospace. A declassified client list includes such giants as Comsat, Contel/American Satellite, Harris Systems International, United Technologies Corp., Imperial Chemical Industries, Sagem, Sikorski Aircraft, Norden Systems, Westinghouse Electronic Systems, Hewlett Packard, Lockheed Martin, Oracle AG, BroadNet Europe, Spacelink International and L-3 Communications.

About Bulldog Technologies

Bulldog Technologies Inc. is a leading provider of wireless security solutions and sensor networks. The Company researches, develops, and manufactures real-time, comprehensive monitoring, intrusion detection, covert asset recovery and tracking BOSS(TM) (Bulldog Online Security Solution) devices and solutions for use in the supply chain, focusing on the cargo transportation and storage industry.

Bulldog's solutions allow dispatchers, security personnel, law enforcement and loss prevention professionals, emergency response teams and cargo transport drivers to monitor, track and secure valuable cargo during the transport, storage and delivery supply chain process.

For further information, visit Bulldog on the Web at http://www.bulldog-tech.com .

SAFE HARBOR STATEMENT: This news release contains "forward-looking statements" that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "future", "plan" or "planned," "will" or "should," "expected," "anticipates," "draft," "eventually" or "projected." You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements, including the risks that our products may not achieve customer acceptance or that they will not perform as expected, that customer trials will not lead to future sales, and other risks identified in our annual report on Form 10-K and other filings with the SEC. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements are made as of the date hereof and Bulldog Technologies Inc. undertakes no obligation to update such statements.

SOURCE: Bulldog Technologies Inc.

Bulldog Technologies Inc.
Jan Roscovich, 604-271-8656
jroscovich@bulldog-tech.com


Copyright Business Wire 2005